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 Mutations in superoxide dismutase 1 (SOD1) are known to cause dominantly-
inherited amyotrophic lateral sclerosis (ALS), a rapidly-fatal adult-onset 
neurodegenerative disorder defined by motor neuron loss and progressive paralysis. In 
the past twenty years, research into the disorder has been driven by the creation of 
numerous transgenic animal models that have yielded multiple theories on the 
pathogenesis of the disease. Patients and animal models with SOD1 mutations express 
the defective protein in every cell, yet the disease only affects tissues in the 
neuromuscular axis. In this dissertation, I present original work exploring two aspects of 
SOD1 ALS. The first details the biochemical characterization of recently discovered 
canine SOD1 mutations that have been found to cause canine degenerative myelopathy 
(DM), the only naturally occurring non-human ALS model. My research showed that, 
like in human ALS and transgenic rodent models, canine DM is accompanied by an 
increase in detergent-insoluble mutant SOD1 in the spinal cords of diseased animals. 
	xii	
Also, these mutations retained full enzymatic activity and aggregate in cell culture, 
confirming that a toxic gain-of-function mechanism is at play in this model. The second 
part of this dissertation describes research into the tissue specificity of the disease. By 
developing a novel stable isotope labeling kinetics (SILK) method to measure long-lived 
proteins, I was able to determine the turnover rate of wild-type, mutant, and misfolded 
SOD1 in rodent tissues both affected and unaffected in disease and in cerebral spinal 
fluid (CSF) from healthy human subjects. The results indicated that SOD1 is a long-lived 
protein with significantly slower turnover in the tissues most affected in ALS. In 
agreement with studies in vitro, the turnover rates for mutant and misfolded SOD1 were 
accelerated compared to wild-type protein, reflecting increased protein instability; yet a 
significant difference in turnover between affected and unaffected tissues remained. 
Finally, by applying this novel SILK method to human subjects, I was able to confirm 
that SOD1 is a long-lived protein in human CSF and, by extension, in the central 
nervous system. These results validate the first method for measuring SOD1 turnover in 
vivo and strongly suggest an important role for the slow turnover of SOD1 in the tissue 
specificity of the ALS. 
	xiii	
PREFACE 
 The contents of this dissertation represent the culmination of four years as a 
graduate student, six years as an MD/PhD student, and, although unrelated in content, 
almost ten years as a scientist-in-training. Although united under the common theme of 
SOD1 and ALS, the original works described herein focus on a two very different pieces 
in the ever-expanding story of this disease. I have written this dissertation with the goal 
of carving out the places in the field where these different pieces fit. As such, this 
document is not an all-inclusive dossier of the literature (a herculean task), but a 
distillation of the relevant pieces needed to understand how these findings expand our 
knowledge in the field of SOD1 ALS. My hope is not only that the reader find conclusive 
evidence for the awarding of a doctoral degree, but that he or she leave with the 
inspiration needed to take this field further to its logical conclusion – an understanding 
and cure for ALS. The basis of this dissertation derives from the following original work. 
Published works have been reprinted with the publisher’s permission. 
Crisp, M. J., Beckett, J., Coates, J. R., & Miller, T. M. (2013). Canine degenerative 
myelopathy: Biochemical characterization of superoxide dismutase 1 in the first 
naturally occurring non-human amyotrophic lateral sclerosis model. Experimental 
Neurology (248):1–9. PMID  23707216 
Crisp, M.J., Mawuenyega, K.G., Patterson, B.W., Reddy, N.C., Chott, R., Self, W.K., 
Weihl, C.C., Jockel-Balsarotti, J., Varadachary, A., Buccelli, R., Yarasheski, K.E., 
Bateman, R.J., & Miller, T.M. (2015). In vivo kinetic approach reveals slow SOD1 
turnover in the CNS. Journal of Clinical Investigation 125(7):2772-80. PMID 
26075819
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“For me, I am driven by two main philosophies: know more today about the world than I knew 
yesterday and lessen the suffering of others. You’d be surprised how far that gets you.” 
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Chapter 1 
The Role of Superoxide Dismutase 1 in Amyotrophic 
Lateral Sclerosis 
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Amyotrophic lateral sclerosis (ALS), colloquially known as Lou Gehrig’s disease, 
is an adult-onset neurodegenerative disorder characterized by the loss of motor 
neurons in the spinal cord and cortex, resulting in a progressive paralysis and death on 
average 2-3 years after symptom onset (Kiernan et al. 2011). With an incidence of 1.5 - 
2.7 cases per 100,000 in North America and Western Europe, ALS is the third most 
common neurodegenerative disorder after Alzheimer’s and Parkinson’s diseases and 
the most common motor neuron disease (Worms 2001). Almost universally fatal, the 
only FDA-approved treatment is Riluzole, a drug that prolongs survival by 2-4 months 
(Cheah et al. 2010). Initially named in the medical literature in 1874 by the prominent 
French physician Jean-Martin Charcot, it was not until 1993 that the first genetic link to 
the disease was discovered in a gene coding for superoxide dismutase 1 (SOD1) 
(Rosen et al. 1993, Rowland 2001). This seminal discovery marked the beginning of an 
ever-accelerating period of biomedical research into the disease that has resulted in the 
discovery of additional causative genes, the creation of numerous animal models, and 
the development of hypotheses into molecular mechanisms and potential treatments. 
However, despite over two decades of fervent research, a cure remains elusive and no 
consensus has emerged on the pathogenesis of the disease. 
 This dissertation will introduce the clinical, pathological, and genetic features of 
SOD1-mediated ALS, discuss the information obtained from the creation and study of 
numerous animal models as well as their advantages and disadvantages, detail the 
tissue specificity of the disease, describe the mechanisms for SOD1 protein turnover, 
and introduce stable isotope labeling kinetics (SILK). It will then describe work 
performed by the author on the biochemical characterization of SOD1 in canine 
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degenerative myelopathy, the most recently discovered and only naturally occurring 
SOD1 ALS model. Then, it will detail studies on SOD1 protein turnover in both a rodent 
ALS model and in human subjects as a window into the tissue specificity of the disease. 
Finally, it will discuss implications of the research in the study of ALS and pertinent 
future directions. 
 
Clinical, Pathological, and Genetic Features of ALS 
 ALS is an adult onset neurological disorder characterized by the progressive loss 
of motor neurons. The clinical presentation of the disorder involves both upper motor 
neuron (UMN) and lower motor neuron (LMN) signs. The site of initial weakness varies 
widely among patients, with approximately 70% of patients presenting with unilateral 
limb onset, approximately 25% presenting with bulbar onset, and 5% presenting with 
respiratory onset (Kiernan et al. 2011). From there, the disease spreads to neighboring 
segments along the neuraxis as additional motor neurons die, resulting in an expanding 
paralysis that eventually affects the muscles of respiration. Most patients ultimately 
succumb to respiratory failure or sequelae from voluntary placement on a respirator 
approximately 2-3 years after disease onset. Sensory deficits can occur in about 32% of 
patients, but these manifestations arise late in the disease and may be complications of 
immobility (Hammad et al. 2007). Interestingly, certain motor neuron populations are 
generally resistant to degeneration until late in the disease, such as those that control 
the pelvic sphincter (Onuf’s nucleus) and extraocular muscles. It has been recently 
shown that these resistant neurons lack the expression of metalloproteinase-9 (Kaplan 
et al. 2014). 
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 Studies have revealed that between 35 and 51 percent of ALS patients display 
cognitive impairment (Lomen-Hoerth et al. 2003, Massman et al. 1996, Ringholz et al. 
2005). Due to overlap between disorders, many have proposed that ALS exists on a 
spectrum with frontotemporal dementia (FTD), a disorder characterized by changes in 
social behavior, personality, or language that accompany degeneration of the frontal 
and temporal lobes (McKhann 2001). The strongest evidence for the ALS-FTD 
spectrum is genetic, with mutations in C9ORF72, TARDBP, FUS, OPTN, and UBQLN2 
causing familial cases of both ALS and FTD (Robberecht & Philips 2013). Both 
disorders can also share similar pathology, dominated by ubiquitinated inclusions that 
contain the mutant protein. The fact that ALS and FTD can coexist is a double-edged 
sword in terms of understanding the mechanism of disease. On one side, unification of 
two previously separate disorders has the potential to extend biological findings to a 
wider set of patients. Conversely, the spectrum of ALS-FTD presentations, disease 
courses, and genetic factors greatly increases the complexity of the disease and 
decreases the likelihood of finding a sole mechanism. 
 The pathology of ALS is characterized by the loss of UMN and LMN in the motor 
cortex and spinal cord, respectively. Reactive gliosis, most evident in the corticospinal 
tracts, occurs concomitantly as neurons are lost. Histologically, a percentage of the 
remaining LMNs possess skein-like inclusions, Lewy body-like round inclusions, 
basophilic inclusions, and, more specific to the disease, Bunina bodies, which are 
eosinophilic inclusions composed of the proteins cystatin C and transferrin (Okamoto et 
al. 2008). With the exception of Bunina bodies, intracellular inclusions stain positive for 
ubiquitin and p62. The presence of additional proteins found in the inclusions, such as 
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SOD1, C9ORF72, TDP-43, FUS, OPTN, UBQLN2, and others, depends on the specific 
genetic or pathological subtype of the disease (Fecto & Siddique 2011). Many of these 
proteins are present in inclusions in FTD as well. As the genetic or pathological causes 
of ALS are clinically indistinguishable and are universally marked by intracellular 
inclusions, many have speculated to a common mechanism of disease. 
 Approximately 90% of ALS is sporadic with no known family history. Inherited 
forms comprise the remaining 10% of cases and have been the major driving force 
behind research (Mitchell & Borasio 2007). The first gene linked to ALS, SOD1, was 
initially described in 1993 and remained the only known causative locus for over a 
decade, accounting for approximately 20% of familial ALS at the time (Rosen et al. 
1993). However, the past eight years have witnessed an explosion in the number of 
discovered genetic causes of ALS to the point where a known genetic etiology accounts 
for about 68% and 11% of familial and sporadic cases, respectively (Renton et al. 
2014). Currently, nine genes have been found to cause ALS, with an additional thirteen 
implicated in the disease. These genes have a diverse set of functions, including RNA 
metabolism (TDP-43 and FUS), protein clearance (SQSTM1, VCP, and UBQLN2), 
vesicle trafficking and cytoskeletal dynamics (OPTN and PFN1), and superoxide 
metabolism (SOD1). Hexanucleotide repeat expansions in C9ORF72, a gene of 
unknown function, were recently discovered and account for the largest portion of 
familial ALS at 40% (DeJesus-Hernandez et al. 2011, Renton et al. 2011). As noted 
above, with the exception of SOD1, many of these genes have also been found to 
cause familial forms of FTD. If ALS and FTD exist on a spectrum, then SOD1-mediated 
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disease marks the purely motor, classically described ALS at one edge of this 
continuum.  
 
Superoxide Dismutase 1: The First Genetic Link to ALS 
 Rosen and colleges initially described 11 different mutations in the SOD1 gene 
responsible for autosomal dominant familial ALS in 1993, revealing the first genetic 
cause of the disease (Rosen et al. 1993). Since that time, the number of mutations that 
have been described number greater than 160 (for an updated list of mutations, see 
http://alsod.iop.kcl.ac.uk/). SOD1 is a 153 amino acid Cu,Zn-metalloenzyme whose 
physiological function is the detoxification of superoxide free radicals into hydrogen 
peroxide and molecular oxygen. Dimerization is required for its function. The protein 
itself contains eight beta sheets interspersed with connecting loops, two intrachain 
disulfide bonds, and metal binding regions. Mutations occur at random throughout the 
protein and impart various degrees of insult to SOD1 structure and function. Some 
mutations disrupt the ability of the protein to bind cations or form dimers, rendering it 
enzymatically inactive and relatively unfolded, while others fall in regions with no 
functional enzymatic deficit. All mutations demonstrate a decrease in protein stability, as 
measured by numerous in vitro studies with recombinant SOD1 (Münch & Bertolotti 
2010, Rodriguez et al. 2002, Tiwari & Hayward 2003). However, there is currently no 
relationship between the degree of protein instability or enzyme function and disease 
course (Ratovitski et al. 1999). 
 SOD1 mutations remain the second most common cause of familial ALS after the 
recently discovered hexanucleotide repeat in C9ORF72. The most recent figures 
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estimate that SOD1 mutations account for 12-20% of familial ALS (Renton et al. 2014, 
Robberecht & Philips 2013). Among the handful of genes that cause ALS, mutations in 
SOD1 are unique in that they present with a purely motor, classical type of ALS with no 
cognitive deficits. Pathologically, the intracellular inclusions in SOD1 ALS motor 
neurons do not stain positive for TDP-43, FUS, OPTN, or the RAN translation products 
of C9ORF72 that are shared by the majority of familial and sporadic cases. Conversely, 
the SOD1 inclusions that characterize SOD1 ALS are almost never seen in familial or 
sporadic cases involving those other proteins. These clinical and pathological 
differences indicate that SOD1 ALS falls on the extreme end of the ALS-FTD spectrum, 
offering a unique window into the purely motor aspect of the disease. 
 Since SOD1 was a well-known protein involved in reducing oxidative stress, the 
logical hypothesis that followed the initial discovery of SOD1 was that ALS resulted from 
a loss of enzymatic function (McNamara & Fridovich 1993). The development of ALS 
animal models soon put this hypothesis to rest. The first transgenic ALS mouse model 
was created in 1994 and overexpressed the human SOD1 mutation G93A (Gurney et 
al. 1994). This mouse developed progressive motor deficits that recapitulated those 
seen in human ALS, including weight loss, muscle spasticity, hindlimb weakness, and 
muscle atrophy that ultimately resulted in death around four months of age. These 
motor deficits were accompanied by pathological changes in the spinal cord that 
included loss of motor neurons, gliosis, and the presence of SOD1 G93A aggregates 
(Dal Canto & Gurney 1995). The G93A mouse was created with endogenous levels of 
mouse SOD1 with an enzymatically active mutant, indicating that a loss of activity was 
not responsible for disease. Furthermore, the SOD1 knockout mouse did not display 
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any signs of disease (Reaume et al. 1996). The results from these studies directed the 
field to focus on a toxic gain-of-function as the pathogenic mechanism of SOD1-
mediated ALS.  
 
Modeling Disease 
 In the twenty years since mutations in SOD1 were found to cause ALS, 
numerous animal models expressing a wide range of SOD1 mutants have been 
created. These models have proven invaluable in learning about the pathogenesis of 
the disease and in screening potential treatments. Although the most common SOD1 
ALS model is the original Gurney mouse overexpressing the human SOD1 G93A 
transgene, the field has borne witness to the development of additional models in the 
mouse, rat, zebrafish, fly, worm, and the discovery of SOD1-mediated naturally 
occurring disease in the dog. Each model carries its own advantages and 
disadvantages that range from the more general (e.g. size, lifespan, ease of creation) to 
more disease specific (e.g. presentation, course, pathology) (Joyce et al. 2011). As 
SOD1 ALS is an autosomal dominant disease that takes decades to manifest, an 
interesting way to look at the available ALS models is to categorize them based on a 
spectrum of most artificial to most physiological. Models thus fall into three distinct 
categories: artificial human transgenic models, artificial endogenous transgenic models, 
and naturally occurring models. Each has offered valuable information into the nature of 
the disease. 
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Artificial human SOD1 transgenic models 
 The logical first step in developing an animal model of most autosomal dominant 
diseases is the insertion of the mutant human transgene into an animal. Thus, the first 
ALS models were constructed in mice and expressed transgenic human SOD1 in 
addition to endogenous mouse SOD1. Currently, over sixteen transgenic mouse models 
have been created with ubiquitous SOD1 expression, twelve of which express naturally 
occurring SOD1 mutations, two that express double or quadruple mutations, and two 
that express human SOD1 WT (Turner & Talbot 2008). Most of these models include 
the full genomic sequence of human SOD1 with its endogenous promoter and requires 
multiple copies for disease onset. However, cDNA driven expression has been shown to 
cause disease in SOD1 G37R mice bred to homozygosity (Wang et al. 2005). Both the 
onset and progression of disease in each mouse model vary depending on the nature 
and expression level of the mutation. For example, mice overexpressing SOD1 G93A, 
G37R, and H46R mutations begin to show signs of disease onset at 3-5 months of age 
that progresses to end stage in 1-2 months (Chang-Hong et al. 2005, Gurney et al. 
1994, Wong et al. 1995). SOD1 G85R and G127X models express lower levels of the 
mutant protein despite multiple copies of the transgene and show signs of disease 
onset at 8 to 14 months with very rapid progression (Bruijn et al. 1997, Jonsson et al. 
2004).  
 Although uncommon, rats overexpressing human SOD1 WT, G93A, or H46R 
transgenes have also been created (Aoki et al. 2005, Chan et al. 1998, Nagai et al. 
2001). The relative size of these animals over mice allows for experiments involving 
surgical manipulations or CSF collection. While the SOD1 WT rats show no signs of 
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disease, the mutant animals recapitulate the disease phenotype seen in the 
corresponding mouse models quite well, with the exception that limb involvement can 
begin with either the hindlimb or forelimb. Like their murine counterparts, disease onset 
is dependent on transgene copy number and the nature of the mutation.  
 Modeling ALS in lower organisms with human SOD1 transgenes has reproduced 
the motor deficits seen in rodent models and human disease. Insertion and 
overexpression of a CMV driven human SOD1 G93A transgene in zebrafish resulted in 
swimming deficits and motor neuron loss preceded by neuromuscular junction and 
axonal damage (Sakowski et al. 2012). In flies, selective overexpression of human 
SOD1 WT, A4V, and G85R resulted in climbing defects, conduction defects, and an 
increased stress response in glia (Watson et al. 2008). However, no motor neuron loss 
or reduction in lifespan were observed, which may be due to the non-cell autonomous 
nature of the disease; mouse studies with selective pan-neuronal or motor neuron 
expression also failed to demonstrate motor neuron loss (Lino et al. 2002, Pramatarova 
et al. 2001, Wang et al. 2008). In worms, ubiquitous expression of human SOD1 mutant 
transgenes, but not SOD WT, imparts a greater sensitivity to oxygen free radical 
damage produced by paraquat (Oeda et al. 2001). Pan-neuronal expression of SOD1 
demonstrated mutant specific neuronal aggregates, locomotion impairments, and 
defects in synaptic transmission (Wang et al. 2009). Others have used selective 
expression in worm body wall muscles to show aggregation propensity of particular 
SOD1 mutants is modulated by genetic background or environmental stress (Gidalevitz 
et al. 2009, Oeda et al. 2001).  
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 Overall, ALS animal models overexpressing transgenic human SOD1 mutants 
have been the major driving force for research. For example, the SOD1 G93A mouse 
model remains the tried and true standard for the disease to this day due to its relatively 
rapid, predictable, and uniform disease onset and progression. One fundamental caveat 
with these models is the artificial nature of their existence. This artificiality is evident in 
that multiple copies of the transgene are required for disease and that the number of 
copies dictates disease course. This is in stark contrast to human ALS, where 
pathogenesis only requires a single mutant copy. Another consideration is the insertion 
of a human gene into a model background. This was a concern in the development of 
the SOD1 A4V mouse, which failed to develop disease unless it was crossed with a 
transgenic SOD1 WT mouse (Deng et al. 2006). The existence of a few studies where 
overexpression of human SOD1 WT also resulted in pathology suggest that high levels 
of the SOD1 protein itself is toxic (Graffmo et al. 2013, Jaarsma 2006, Jaarsma et al. 
2000). Regardless, transgenic human SOD1 mutant models offer the most reliable, well 
characterized, and translatable disease model for laboratory research. 
  
Artificial endogenous SOD1 transgenic models 
 Though not nearly as numerous as ALS models expressing the human SOD1 
transgene, a couple animal models have been developed that overexpress mutations in 
endogenous SOD1. The most noteworthy case is the SOD1 G86R mouse, which 
overexpressed a missense mutation in murine SOD1 (mSOD1) at a residue conserved 
in human SOD1. This was actually the first ALS model mouse created but published a 
few months after the Gurney SOD1 G93A mouse (Ripps et al. 1995). Like its human 
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transgenic SOD1 G93A counterpart, it developed hindlimb paralysis and tail spasticity 
around 3-4 months of age accompanied by motor neuron loss, SOD1 aggregates, and 
reduced survival. The other example was in zebrafish that overexpressed native SOD1 
WT or a SOD1 G93R mutation under the SOD1 promoter. These fish displayed mutant-
dependent motor deficits, SOD1 aggregates, early NMJ loss, progressive motor neuron 
loss, and reduced survival (Ramesh et al. 2010). 
 These models offer insight into the role that SOD1 plays in motor neuron 
degeneration across species. SOD1 is highly conserved in eukaryotes, implying that 
changes in its primary sequence have not been well tolerated throughout evolution. 
Indeed, the fact that over 160 mutations in more than 70 out of 153 residues have been 
discovered to cause protein misfolding in human ALS suggests that the folded structure 
of SOD1 is intolerant to perturbation. In the least, the fact that mutations in the 
endogenous SOD1 of mice and zebrafish replicate human disease raises the possibility 
of an evolutionarily conserved mechanism for motor neuron degeneration. Such a 
finding offers strong validation for both human and endogenous SOD1 transgenic 
models of disease. Interestingly, however, crossing the mSOD1 G86R mouse with the 
transgenic hSOD1 WT mouse does not increase disease progression, unlike studies 
with hSOD1 mutant and WT double transgenic mice (Audet et al. 2010). Biochemically, 
mSOD1 and hSOD1 do not interact as indicated by the lack of detectable chimeric 
heterodimers or aggregates in these double transgenic animals. Recent evidence 
shows that the primary sequence divergence, specifically the tryptophan-32 residue 
unique to hSOD1, may account for this phenomenon (Grad et al. 2011). Overall, 
species-specific SOD1 mutations offer a unique angle into some of the more recently 
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proposed mechanisms of disease, such as cellular uptake of the mutant and the 
propagation of misfolded species. 
 
Naturally occurring models 
 While the transgenic ALS models described above have contributed important 
information to the potential mechanisms of SOD1 ALS in the timescales required for 
typical laboratory research, they remain artificial in their dependence on the expression 
of multiple transgene copies. Transgenic models are also poor choices in trying to 
model the effects of age or environment on ALS in the background of short lifespans. 
After all, a major risk factor for the development of ALS is age. Specifically, the 
incidence of ALS increases with age, especially after the 4th decade, and peaks at age 
74, indicating that environment or age-related factors play a significant role in 
developing disease (Worms 2001).  
In 2009, genome-wide association studies (GWAS) linked a mutation in canine 
SOD1 (cSOD1) to cases of canine degenerative myelopathy (DM) in multiple dog 
breeds (Awano et al. 2009). Two years later, another group found a second cSOD1 
mutation in a Bernese Mountain dog with canine DM (Wininger et al. 2011). Canine DM 
affects multiple dog breeds toward the latter half of their lifespan and is characterized by 
an often asymmetric onset of paraparesis and ataxia in the hind limbs that progresses 
to paraplegia and muscle atrophy within one year from onset of signs. Although the 
entire course of the disease can last as long as 3 years, many owners elect for 
euthanasia. However, those dogs that have been allowed to progress show ascension 
of the disease to include the forelimbs, ultimately resulting in flaccid tetraplegia and 
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dysphagia (Coates & Wininger 2010, Shelton et al. 2012). Histopathology of spinal 
cords from affected dogs show a similar pattern of myelin and axonal loss and 
astrogliosis seen in human ALS, and immunohistochemistry reveals the same SOD1 
aggregates in motor neurons that are present in humans and rodent models with 
hSOD1 mutations. Interestingly, unlike human ALS, canine DM is mostly autosomal 
recessive – a small amount of dogs heterozygous for SOD1 mutations did display 
disease – and incompletely penetrant (Zeng et al. 2014). Also, the disease differs from 
human ALS in that proprioceptive pathways are affected, dorsal root ganglion neurons 
degenerate, motor neuron loss is less severe, and muscle atrophy occurs irrespective of 
denervation (Morgan et al. 2013, 2014).  
 The significance of linking SOD1 to canine DM is that canine DM marks the first 
naturally occurring SOD1 ALS model. This opened up many questions into the nature of 
cSOD1 mutants. For example, as a majority of canine DM is autosomal recessive, an 
important question was whether this disease was a result of a loss of enzymatic function 
or a toxic gain-of-function. It was also unknown if cSOD1 mutants formed the same 
detergent-insoluble aggregates in the spinal cord of affected dogs as seen in human 
ALS and transgenic models. Additionally, no one had cloned cSOD1 WT or the E40K 
and T18S mutations to study their aggregation propensities in relation to hSOD1. 
Chapter 2 of this dissertation details work addressing each of these questions. The 
results confirm many biochemical similarities between the cSOD1 and hSOD1 mutants 
and lend further credence to canine DM as an ALS model organism. 
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Tissue Specificity in SOD1 ALS 
 As previously stated, ALS is clinically and pathologically defined by a loss of 
motor neurons in the spinal cord and cortex accompanied by atrophy of skeletal 
muscles. However, when one considers the ubiquitous expression of SOD1 throughout 
an organism, the tissue and cellular specificity of the disease are puzzling. After all, 
intracellular SOD1 concentrations are substantial, comprising up to 1% of all protein in 
the CNS, yet can reach higher absolute concentrations in the liver and kidney (Jonsson 
et al. 2008, Pardo et al. 1995, Zetterström et al. 2007). This relative difference between 
tissues is also seen with endogenous mSOD1 and transgenic hSOD1 in normal and 
ALS mice, respectively (Jonsson et al. 2006, Wang et al. 2002). The general lack of 
pathology in unaffected tissues presents an interesting question as to how these tissues 
handle mutant SOD1 differently from the CNS. 
While SOD1 aggregates are generally not reported in tissues unaffected in 
disease (i.e. liver, kidney), there have been a few reports in the literature that suggest 
even these tissues may be susceptible to pathogenesis. One case report of a 34-year-
old woman with Downs Syndrome and SOD1 ALS described finding SOD1 
immunopositive inclusions in hepatocytes at autopsy (Marucci et al. 2007). Interestingly, 
Downs Syndrome patients have higher levels of SOD1, as the SOD1 genetic locus is on 
the 21st chromosome (Gulesserian et al. 2001). This case was unique in that this 
woman possessed two SOD1 S134N missense mutations and one wild-type copy. The 
fact that her 70-year-old mother was heterozygous for the mutation but unaffected by 
disease implied that increased gene dosage played a role in pathogenesis in a similar 
manner to how disease onset and severity correlate with gene dosage in numerous 
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animal models. It also argued for the existence of a general susceptibility to SOD1 
aggregation in other tissues as a result of increased mutant protein burden. Another 
case report analyzed autopsy tissues from a SOD1 G127X patient using a mutant-
specific antibody and found high molecular weight species in the liver and kidney via 
density-gradient centrifugation as well as SOD1 immunopositive inclusions in kidney 
tubular epithelium and hepatocytes (Jonsson et al. 2008). Although the antibody used 
was more sensitive and specific for the G127X mutant, the novelty of this finding is 
probably a result of many groups failing to look at SOD1 pathology outside of the 
neuromuscular axis. In animals, one study looking at the accumulation of hydrophobic, 
misfolded SOD1 species in affected and non-affected tissues of a G93A mouse model 
confirmed that these species exist and also accumulate in the liver and kidney, albeit to 
a significantly lesser degree than the spinal cord and brain (Zetterström et al. 2007). In 
these studies, the level of aggregated SOD1 found in these non-affected tissues was 
still a fraction of that found in the CNS, yet they suggest a common mechanism for 
SOD1 aggregation that may be modulated by the intrinsic ability for a tissue to clear 
toxic SOD1 species. 
 Disease specificity also extends to the cellular level within the CNS, as motor 
neurons are lost and other cell types are spared despite ubiquitous SOD1 expression. 
Even within motor neuron pools, the selective degradation does not extend to those in 
the occulomotor nuclei and Onuf’s nucleus. This observation was recently linked to 
differential expression of metalloproteinase-9 in motor neuron pools and suggests a 
heterogeneity even among motor neurons (Kaplan et al. 2014). Traditionally, motor 
neurons are the cells most affected in ALS, yet studies have demonstrated that the 
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development of disease in SOD1 ALS is at least partially non-cell autonomous (Ilieva et 
al. 2009). Numerous conditional mouse models have been created with expression of 
mutant SOD1 restricted to specific cell types, including astrocytes, pre- and post-natal 
neurons, and microglia, yet not one of these models developed disease (Beers et al. 
2006, Gong et al. 2000, Lino et al. 2002, Pramatarova et al. 2001). Mice with selective 
expression of mutant SOD1 in motor neurons and interneurons failed to develop 
weakness, but did show weight loss and some motor neuron loss with ubiquitinated 
inclusions (Wang et al. 2008). Muscle specific expression of SOD1 was shown to 
induce muscle pathology, weakness, and, in one study, motor neuron loss in mice 
(Dobrowolny et al. 2008, Wong & Martin 2010). However, this was likely due to an 
artifact of SOD1 overexpression, as SOD1 WT animals also showed the same 
pathology. Only animals with homozygous PrP-driven SOD1 G37R in neurons, 
astrocytes, and muscle displayed a neuromuscular phenotype, implying that the 
interplay between these cell types is required (Wang et al. 2005).  
Interestingly, SOD1 transgenic mice with Cre-mediated excision of mutant SOD1 
from specific cells types develop disease, but on a modified timeline. Removal of mutant 
SOD1 from microglia or astrocytes has been shown to delay disease progression, while 
removal from motor neuron pools resulted in a delay in disease onset (Boillée et al. 
2006, Yamanaka et al. 2008). These data suggest that motor neurons may be 
responsible for the initial manifestations of the disease, while microglia and astrocytes 
play a larger role during later stages. Despite these observations, how this ubiquitously 
expressed mutant protein is selectively toxic to certain cells of the neuromuscular 
system has been a long-standing question in the field.  
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A Role for Protein Turnover 
Protein turnover is a collective term that involves both the production and 
clearance rates of a protein in a cell and has important implications for many diseases. 
Turnover is a basic characteristic of proteins that dictates their steady-state levels in a 
cell or tissue. How long a synthesized protein remains in a cell is influenced by many 
factors. At the level of the protein itself, structural stability and biochemical properties 
(e.g. amino terminal residue, sequence motifs, hydrophobicity) influence protein 
turnover (Bachmair et al. 1986, Dice & Goldberg 1975a,b; Tompa et al. 2008). For 
example, it is well documented that many misfolded proteins are rapidly degraded, such 
as mutant cystic fibrosis transmembrane conductance regulator (CFTR) responsible for 
cystic fibrosis (Sun et al. 2006). Forces beyond individual protein structure are also at 
play in dictating turnover rate. These include transcriptional and translational regulation, 
the presence of interacting chaperones, subcellular sequestration of proteins, and the 
activities of the ubiquitin-proteasome system and autophagy. Dynamic interplay 
between these forces is responsible for the lifespan of a protein. 
The susceptibility of the CNS in the development of many degenerative disorders 
involving protein aggregation may be a result of its intrinsically slower protein turnover 
rate. The best evidence for this comes from two studies utilizing stable isotope labeling 
and mass spectrometry to determine turnover rates for a multitude of proteins in 
rodents. The first study administered a diet of 100% 15N-labeled amino acids to mice, 
which were incorporated into newly synthesized proteins over time (Price et al. 2010a). 
The extent of this incorporation was tracked by sacrificing the animals at different time 
points, collecting tissue, and detecting and analyzing the amount of incorporated label 
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into many proteins via mass spectrometry and a sophisticated data analysis algorithm 
(Guan et al. 2011). From this method, the turnover rates for over 1010, 1122, and 334 
proteins in brain, liver, and blood, respectively, were calculated. The average half-life for 
brain proteins was about 9 days, while the average for liver and blood proteins were 3 
and 3.5 days, respectively. When the turnover rates of identical proteins were compared 
between tissues, proteins in the brain were always longer lived than their counterparts 
in the liver. A second study administered a 100% 15N-labeled diet to pregnant rats and 
their pups through 6 weeks of age, then switched to a normal diet and sacrificed the 
animals at six and twelve months (Savas et al. 2012). Using mass spectrometry, this 
group was able to detect the presence of 15N-labeled proteins in the liver and brain and 
discovered that the lifespan of certain nucleoporins equaled the lifespan of the animal. 
Importantly, at each time point, the brain had significantly more labeled proteins than 
the liver, indicating its relatively reduced rate of turnover.  
 Turnover of SOD1 has been well studied in cell culture. Significantly increased 
clearance rates for mutants compared to wild-type protein have been repeatedly 
demonstrated using a radiolabel pulse-chase paradigm (Borchelt et al. 1994, Hoffman 
et al. 1996, Johnston et al. 2000, Ratovitski et al. 1999). The degree of accelerated 
turnover correlates with the general structural instability of the protein, with the dimer-
interface (A4V) and metal binding site (G85R) mutants decaying significantly faster than 
the more benign enzymatically active mutants (G93A). The relatively increased turnover 
rate of mutant SOD1 seen in cell cultures has also been observed in a C. elegans 
model overexpressing mutant SOD1 as well as in the spinal cord of a SOD1 G85R-YFP 
mouse model using deuterium-exchange labeling kinetics (Farr et al. 2011, Oeda et al. 
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2001). In humans, examining the ratio of mutant to wild-type SOD1 in erythrocytes, 
which no longer synthesize protein, from numerous SOD1 ALS patients confirmed 
faster turnover of mutants in humans and correlated this accelerated turnover to 
disease progression (Sato et al. 2005).  
Faster turnover of mutant SOD1 may be a result of its preferential targeting by 
protein clearance mechanisms. It has been shown that the mechanisms responsible for 
SOD1 clearance include both the ubiquitin-proteasome system (UPS) and autophagy 
(Di Noto et al. 2005, Hoffman et al. 1996, Kabuta et al. 2006, Puttaparthi et al. 2004, 
Urushitani et al. 2002). Interestingly, studies have demonstrated that SOD1 mutants are 
preferentially ubiquitinated by the E3 ligases Dorfin and NEDL1, and that the degree of 
ubiquitination correlates with the disease severity of the mutation (Miyazaki et al. 2004, 
Niwa et al. 2002). Overexpression of Dorfin reduced mutant SOD1 levels, ameliorated 
cellular toxicity, reduced the activation of the cytochrome-caspase system in 
mitochondria, and prolonged survival in both cell culture and SOD1 G93A mice (Sone et 
al. 2010, Takeuchi et al. 2004). Additionally, chemical inhibition of autophagy 
preferentially increased levels of mutant SOD1, indicating that the mutant forms are 
preferentially targeted by this pathway (Kabuta et al. 2006). It has been well established 
that chemical inhibition of either the UPS or autophagy results in an increase in SOD1 
aggregates and cell death while enhancement reverses this toxicity, indicating that cells 
are exquisitely sensitive to perturbations in SOD1 protein clearance and subsequent 
increases in steady-state levels. This parallels the correlation between gene dosage 
and disease severity in many SOD1 ALS animal models.  
	
	
22	
 Many groups have examined the role of the UPS and autophagy in animal 
models of SOD1 ALS. Proteasome activity has been shown to decrease with age in 
normal mice, suggesting a link between the UPS, age, and disease onset (Keller et al. 
2000). However, limited attempts to globally reduce UPS activity in SOD1 mice via 
genetic crosses have yielded no significant differences in disease course. SOD1 G93A 
mice crossed with LMP2 knockout mice, which lack an essential subunit of the 
immunoproteasome, failed to exacerbate disease (Puttaparthi et al. 2007). Crosses 
between SOD1 G93A mice and mice overexpressing human ubiquitin or the dominant-
negative UbK48R mutation also failed to modify disease (Gilchrist et al. 2005). Mutant 
SOD1 has been shown to accumulate in the spinal cord independent of gene 
expression as the disease progresses, indicating reduced clearance, yet is 
unaccompanied by reduced proteasome activity in the spinal cord (Cheroni et al. 2005). 
However, the failure to observe a deficit in proteasome activity in the spinal cord may be 
the result of cellular mixing with homogenization of the entire cord. By crossing SOD1 
G93A mice with the UPS reporter UbG76V-GFP, one study demonstrated a reduction in 
proteasome activity late in the disease in motor neurons (Cheroni et al. 2009).  
The role of autophagy manipulation in SOD1 ALS has been conflicting. Although 
one study reported a reduction in SOD1 levels and cellular toxicity in culture with the 
MTOR inhibitor rapamycin (Kabuta et al. 2006), two studies administering rapamycin to 
SOD1 mice showed no effect (Bhattacharya et al. 2012) or exacerbated the disease 
(Zhang et al. 2011) despite increased autophagy markers in the spinal cord. This may 
be due to the involvement of MTOR in many other cellular processes, such as cell 
growth, protein and lipid synthesis, and energy metabolism (Laplante & Sabatini 2012). 
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Indeed, activation of the MTOR-independent autophagy pathway with the disaccharide 
trehalose did reduce SOD1 mutant levels in cell culture and extend survival in ALS mice 
(Castillo et al. 2013, Gomes et al. 2010). Overall, these studies suggest a role for 
protein clearance in the pathogenesis of SOD1 and highlight the need develop methods 
to examine the kinetics of protein clearance in vivo. 
 
Stable Isotope Labeling Kinetics (SILK) 
Pulse-chase methodologies utilizing radiolabeled amino acids have been a 
reliable tool for calculating protein turnover for many decades (Toyama & Hetzer 2013). 
However, for safety and environmental reasons, the use of radiolabels is less than ideal 
for experimentation outside of cell culture. Measuring turnover rates of proteins in an 
immortalized, rapidly dividing cell culture model also has its limitations. For one, 
turnover rates are faster, as rapid cell division dilutes the labeled pool by half with each 
round of the cell cycle. Also, such rapid division requires a greater metabolic demand in 
terms of protein synthesis and degradation, resulting in an accelerated picture of protein 
turnover compared to much less active tissues. Indeed, this discrepancy is evident 
when turnover rates for identical proteins were compared between tissues and cell 
culture models (Price et al. 2010b). Therefore, to obtain the most physiological picture 
of protein turnover in vivo, the safest method is to use stable isotope labeling to monitor 
the production and clearance of proteins in tissue. 
 SILK requires the administration of a non-radioactive (i.e. stable) isotopically 
labeled amino acid over time that is incorporated into newly synthesized proteins. The 
carbon and nitrogen atoms in these tracer amino acids are replaced with 13C or 15N 
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isotopes, which results in an amino acid with increased mass but identical chemical 
properties. The choice of which tracer amino acid to use depends on a number of 
factors, such as cost, the presence of the amino acid in peptides generated from 
protease digestion of the target protein, and the metabolism of the amino acid (e.g. 
essential versus non-essential) (Wolfe & Chinkes 2005). Commonly used amino acids 
include 13C6-leucine, 13C6-lysine, 13C6-arginine, 13C9-phenylalanine, and their 15N 
variants. The incorporation of the tracer amino acid into the target protein results in a 
positive shift in the mass/charge (m/z) ratio of proteolytic peptides, which can be 
detected and quantified via mass spectrometry to determine a tracer:tracee ratio (TTR) 
(Previs et al. 2012). The rate of change in TTR over time is then used to calculate the 
protein fractional turnover rate (FTR), expressed as the percent of a protein pool that is 
turned over per unit time. This number can be converted into a half-life by dividing the 
FTR from the natural log of 2, expressed in units of time. The FTR is a function of two 
different kinetic rates for a protein population: the fractional synthetic rate (FSR) and the 
fractional catabolic rate (FCR), or the rate of protein synthesis and degradation, 
respectively. Assuming no changes in the steady-state levels of a protein over time, 
FSR, FCR, and FTR are equivalent values.  
  The simplest models for stable isotope labeling involve a single compartment as 
the sole source of the tracer amino acid (also called the precursor pool for protein 
synthesis) at a steady-state level of tracer. For example, cells in a dish immediately 
exposed to fresh media containing 20% labeled amino acid. Newly synthesized proteins 
will begin to incorporate the stable labeled amino acid rapidly at first and then the rate 
will begin to taper off until the amount of labeled amino acid incorporated into a given 
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protein approaches 20%. On a graph of TTR versus time, the shape of this curve will be 
dictated by equation 1 
Protein label = precursor enrichment x (1 - e-FTR x time)   (1) 
where precursor enrichment specifies the tracer concentration and FTR is the fractional 
turnover rate. The faster the FTR, the faster the TTR curve for a particular protein will 
reach a steady-state level of label. If a steady-state level of label incorporation is not 
achieved for a target protein, the FTR can be estimated using equation 2 
FTR = pseudo-linear change in protein labeling /  
(precursor enrichment x time)       (2) 
where the pseudo-linear change in protein labeling represents the initial “linear” portion 
of the curve before tapering. This approach has been successfully applied to estimating 
an FSR for beta-amyloid in human CSF (Bateman et al. 2006, 2007; Mawuenyega et al. 
2010). 
 In addition to measuring label incorporation into a protein of interest in the 
presence of a tracer, one can also measure the clearance of label from the protein of 
interest in the absence of tracer. This type of kinetic analysis is frequently employed in 
radiolabeled pulse-chase assays measuring the disappearance of radiolabeled protein 
over time. The goal for this type of analysis is to label a protein of interest in the 
presence of a tracer amino acid, then remove said tracer and measure the rate of 
disappearance of the labeled amino acid from the target protein (decay rate). For 
example, cells grown to confluence in the presence of 20% tracer followed by a switch 
to unlabeled media. Assuming first-order kinetics with no contribution of tracer recycling, 
equation 3 can be used to determine the FTR. 
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FTR = ln (ΔTTR / Δtime)     (3) 
The decision to measure tracer incorporation into a protein or its clearance depends on 
a number of factors, such as the turnover rate of the protein, toxicity of expression, 
changes in protein concentration, and cell culture lifespan. Again, assuming steady-
state levels of a protein, equations 1 and 3 should yield equivalent measures of the 
FTR. However, if there is a disconnect between synthesis and degradation (e.g. 
increases or decreases in protein levels) then examining both equations is warranted. 
Indeed, such a discrepancy has been found for beta-amyloid clearance in the patients 
with Alzheimer’s disease and presenilin mutations (Mawuenyega et al. 2010, Potter et 
al. 2013). 
 Measuring protein turnover becomes more complicated in the setting of animal or 
human studies due to less control over the kinetics of the tracer precursor pool. Unlike 
cell culture models where tracer availability is determined by media composition that 
can be rapidly changed, administering tracer amino acids to whole organisms involves a 
bolus, constant infusion, or a combination of both in order to increase and then maintain 
the concentration of tracer. This is because one cannot simply switch out all of the 
unlabeled amino acid with a labeled amino acid, but instead has to introduce the labeled 
amino acid in the setting of an existing unlabeled amino acid pool. Even when 
administering 100% tracer, there exists a gradual rise in the plasma concentration as 
the tracer diffuses through the animal and is exchanged among tissues. On the opposite 
end of the labeling curve, abatement of labeling does not result in instantaneous 
elimination from amino acid pools. Instead, the nature of first-order decay coupled with 
contributions from recycling of tracer from body stores results in some residual 
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concentration of tracer that contributes to protein synthesis. Thus, the kinetics of the 
tracer itself become a differential variable in equation 1 and must be accounted for in 
equation 3.  
One important consideration in designing a SILK study to measure a long-lived 
protein is the method of tracer administration and sample collection. A protein with a 
short half-life (i.e. hours) can be measured by an intravenous tracer infusion with 
multiple sample collection points lasting a few hours. This is because a significant 
fraction of the protein pool will be turned over every hour (50% during one half-life). 
Such a design has been highly successful in measuring CSF β-amyloid turnover in 
human CSF, where subjects received a constant infusion of intravenous 13C6-leucine 
and CSF was collected hourly via a catheter inserted over a 48 hour period (Bateman et 
al. 2006, 2007; Mawuenyega et al. 2010). However, for a longer-lived protein with a 
half-life on the order of days or weeks, an intravenous infusion would require days in 
order to ensure label uptake into newly synthesized protein and is unlikely to be 
tolerated. Additionally, sample collection would be required to be further out from the 
administration of tracer to allow for the full measurement of the kinetic curve (i.e. the 
increasing and decreasing components). As SOD1 is hypothesized to be a long-lived 
protein in the CNS, a novel labeling method was needed to deliver a sufficient dose of 
tracer over a long period and sample collection points taken days later. In Chapter 3 of 
this dissertation, I describe the development of a SILK method utilizing oral 
administration of the tracer 13C6-leucine to both ALS animal models and healthy human 
subjects to show that SOD1 is relatively long-lived in the tissues most affected in 
disease. 
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Summary of Findings 
 The work detailed in the following pages represents new insights into two of the 
many facets of SOD1 ALS biology. Chapter 2 details the first biochemical 
characterization of the only two existing canine SOD1 mutants responsible for canine 
DM. This work found that cSOD1 mutants have multiple similarities with hSOD1 
mutants, including the accumulation of detergent-insoluble aggregates in the spinal cord 
of affected dogs, an increased propensity to aggregate in the presence of denaturants 
and in cell culture, and the ability to form enzymatically active dimers, lending strong 
support to a similar toxic gain-of-function mechanism in the only naturally-occurring 
model of ALS. Chapter 3 describes original work developing a SILK method to measure 
long-lived protein SOD1 kinetics in both animal models and healthy human subjects. 
Using a rat ALS model, we found that SOD1 WT turnover is significantly slower in 
neuromuscular tissues (i.e. cortex, spinal cord, muscle) than tissues not affected by 
disease (i.e. liver and kidney). This relative difference was also true for the SOD1 G93A 
mutant. When we looked at the misfolded SOD1 mutant pool in the spinal cord and 
liver, we found a significantly accelerated turnover rate compared to total SOD1, but the 
same relative difference in turnover between the spinal cord and liver. We were able to 
successfully adapt our SILK method to measure SOD1 turnover in the CSF of healthy 
human subjects, marking the first time that an orally administered tracer amino acid has 
been used to measure long-lived proteins in humans. We found that SOD1 turnover in 
the CSF is approximately four-fold slower than the total CSF protein pool, replicating our 
results in CSF from ALS rats, confirming that SOD1 is a long-lived protein in the CNS, 
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and providing a foundation for future studies looking at SOD1 turnover in patients with 
SOD1 mutations. 
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Chapter 2 
Canine Degenerative Myelopathy: Biochemical 
Characterization of Superoxide Dismutase 1 in the First 
Naturally Occurring Non-human Amyotrophic Lateral 
Sclerosis Model  
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ABSTRACT 
Mutations in canine superoxide dismutase 1 (SOD1) have recently been shown 
to cause canine degenerative myelopathy, a disabling neurodegenerative disorder 
affecting specific breeds of dogs characterized by progressive motor neuron loss and 
paralysis until death, or more common, euthanasia. This discovery makes canine 
degenerative myelopathy the first and only naturally occurring non-human model of 
amyotrophic lateral sclerosis (ALS), closely paralleling the clinical, pathological, and 
genetic presentation of its human counterpart, SOD1-mediated familial ALS. To further 
understand the biochemical role that canine SOD1 plays in this disease and how it may 
be similar to human SOD1, we characterized the only two SOD1 mutations described in 
affected dogs to date, E40K and T18S. We show that a detergent-insoluble species of 
mutant SOD1 is present in spinal cords of affected dogs that increases with disease 
progression. Our in vitro results indicate that both canine SOD1 mutants form 
enzymatically active dimers, arguing against a loss of function in affected homozygous 
animals. Further studies show that these mutants, like most human SOD1 mutants, 
have an increased propensity to form aggregates in cell culture, with 10-20% of cells 
possessing visible aggregates. Creation of the E40K mutation in human SOD1 
recapitulates the normal enzymatic activity but not the aggregation propensity seen with 
the canine mutant. Our findings lend strong biochemical support to the toxic role of 
SOD1 in canine degenerative myelopathy and establish close parallels for the role 
mutant SOD1 plays in both canine and human disorders. 
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INTRODUCTION 
For two decades, data from human studies and transgenic animal models have 
shown that mutations in superoxide dismutase 1 (SOD1) cause a form of dominantly-
inherited amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder 
resulting in motor neuron loss, paralysis, and death 3-5 years after symptom onset 
(Kiernan et al 2011; Rosen et al 1993; Turner & Talbot 2008). To date, over 160 
mutations have been identified in SOD1, which normally functions as a Cu,Zn-
metalloenzyme that converts superoxide anions to molecular oxygen and H2O2 (for a list 
of mutations, see http://alsod.iop.kcl.ac.uk/). Although SOD1 mutations occur 
throughout the protein and result in a range of disease durations, they are united in their 
reduced stability and increased ability to aggregate. In fact, SOD1 aggregates in motor 
neurons are the histopathological hallmark of SOD1 ALS, a property that extends to 
animal models, cell culture overexpression systems, and experiments with recombinant 
protein. As SOD1-mediated ALS is a dominantly-inherited disease, this toxic gain of 
function becomes important in the setting of the remaining functional copy of wild-type 
(WT) SOD1, yet the mechanism responsible for how this toxic gain of function 
contributes to disease is unknown.  
Until recently, with the exception of the artificial G86R and G93R mutations 
created in mouse and zebrafish SOD1, respectively, humans were the only organisms 
in which ALS occurred, and the only organisms where mutations in SOD1 responsible 
for causing this disease have been described (Ramesh et al 2010; Ripps et al 1995). 
That changed with GWAS data linking a mutation in canine SOD1 (cSOD1) to canine 
degenerative myelopathy (DM), a progressive neurodegenerative disorder in dogs with 
striking similarities to the clinical progression of human ALS (Awano et al 2009). 
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Specifically, canine DM affects multiple dog breeds toward the latter half of their lifespan 
and is characterized by an often asymmetric onset of paraparesis and ataxia in the hind 
limbs that progresses to paraplegia and muscle atrophy within one year from onset of 
signs. Although elective euthanasia occurs for a majority of these dogs by this stage, 
those that have been allowed to progress show ascension of the disease to include the 
forelimbs, ultimately resulting in flaccid tetraplegia and dysphagia. The entire course of 
the disease can last as long as 3 years (Coates & Wininger 2010). Histopathology of 
spinal cords from affected dogs show a similar pattern of myelin and axonal loss 
replaced with astrogliosis seen in human ALS, and immunohistochemistry reveals the 
same SOD1 aggregates in motor neurons that are present in humans and rodent 
models with human SOD1 (hSOD1) mutations (Awano et al 2009; Bruijn 1998).  
Dog models of human disease offer specific advantages over traditional rodent 
models. For example, many human diseases occur naturally in dogs that would 
otherwise need to be artificially induced in rodent models. Furthermore, the limited 
genetic diversity of dog breeds, faster aging, shared environment with humans, and 
availability of advanced medical care facilitate expedited clinical trials for promising 
pharmacological agents targeting human disease. One example is that many canine 
models of human cancers, which develop sporadically in dogs, have been found to 
share several genetic similarities with human cancers and have been successfully used 
in clinical trials (Rankin et al 2012; Rowell et al 2011). Therefore, with these advantages 
in mind, further characterization of the canine model of ALS is warranted. Here, we 
report the first biochemical characterization of the only two cSOD1 mutations known to 
be associated with canine DM – the E40K mutation originally described in a number of 
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breeds and the T18S mutation from a case report detailing a Bernese Mountain dog 
with canine DM (Awano et al 2009; Wininger et al 2011). We show that spinal cords of 
DM dogs contain detergent-insoluble mutant SOD1 that correlates with disease severity 
and that both mutants are enzymatically active dimers that possess an increased 
aggregation propensity in vitro. Our results elucidate important similarities between 
human and canine SOD1 with respect to enzymatic function and aggregation 
propensity, adding a biochemical dimension to the clinical and histopathological 
similarities between canine DM and SOD1-mediated human ALS.  
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METHODS 
Detergent extraction of SOD1 aggregates 
Frozen thoracic spinal cord sections were obtained from age-matched control 
dogs and dogs with increasing severity of canine DM. Detergent extraction of SOD1 
aggregates was preformed as previously described (Prudencio et al 2010). Briefly, 100 
mg of frozen tissue was thawed on ice and homogenized via hand blender in 10 w/v 
TEN buffer (10 mM Tris, pH 8, 1 mM EDTA, 100 mM NaCl) with protease inhibitors 
(Sigma). The homogenate was then mixed with an equal volume of 2X Extraction Buffer 
(10 mM Tris, pH 8, 1 mM EDTA, 100 mM NaCl, 1% NP-40, protease inhibitors), mixed 
via sonication, and spun cold at 100,000xg for 10 minutes in a Beckman Ultracentrifuge. 
The supernatant, representing the detergent soluble fraction S1, was transferred to a 
new tube. The pellet was washed twice by resuspension in 1X extraction buffer via 
sonication and spun at 100,000xg for 10 minutes, cold. After the final wash, the 
supernatant was discarded and the pellet, designated as P2, resuspended via 
sonication in Buffer 3 (10 mM Tris, pH 8, 1 mM EDTA, 100 mM NaCl, 0.5% NP-40, 
0.25% SDS, 0.5% Na-deoxycholate, protease inhibitors). Protein concentration for the 
S1 and P2 fractions was determined by BCA assay (Pierce). The experiment was 
repeated once. 
 
Generation of SOD1 Constructs 
Total RNA was extracted with TRIzol (Invitrogen) from frozen brain tissue 
obtained from control and DM-affected dogs according to the manufacturer’s protocol. 
Total RNA was then reverse transcribed using oligo dT primers to generate cDNA 
(SuperScript III First-Strand Synthesis System for RT-PCR, Invitrogen). Wild-type (WT) 
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and E40K cSOD1 were amplified via PCR using primers with engineered restriction 
endonuclease sites at the 5’ ends. To subclone cSOD1 cDNA into pGEX4T-1 (GE 
Healthcare) using EcoRI and NotI, the forward primer was 5’-
agtcgaattcATGGAGATGAAGGCCGTGTGC-3’ and the reverse primer was 5’-
atcggcggccgcTTATTGGGCGATCCCAATGACA-3’. To subclone into pEYFP-C1 
(Clontech) using EcoRI and BamHI, the forward primer was 5’-
agtcgaattcaATGGAGATGAAGGCCGTGTGC -3’and the reverse primer was 5’-
atcgggatccTTATTGGGCGATCCCAATGACA-3’. The T18S mutant was obtained by 
site-directed mutagenesis of the wild-type SOD1 using the primers 5’-
GTGGAGGGCTCCATCCACTTCGTGCAGAAG-3’ and 5’-
CTTCTGCACGAAGTGGATGGAGCCCTCCAC-3’. Positive clones were verified by 
sequencing and subcloned into pGEX4T-1 and pEYFP-C1 using primers previously 
described. The human E40K mutant was generated via site-directed mutagenesis of 
wild-type hSOD1 using the primers 5’-
GCATTAAAGGACTGACTAAAGGCCTGCATGGATTC-3’ and 5’-
GAATCCATGCAGGCCTTTAGTCAGTCCTTTAATGC-3’. The human E40G mutant was 
similarly generated using the primers 5’-
GCATTAAAGGACTGACTGGAGGCCTGCATGGATTC-3’ and 5’-
GAATCCATGCAGGCCTCCAGTCAGTCCTTTAATGC-3’. Positive clones were verified 
by sequencing and subcloned into pEYFP-C1 with the primers 5’-
agtcgaattcaGCCACGAAGGCCGTGT-3’ and 5’- 
atcgggatccTTATTGGGCGATCCCAATTACACC-3’ and the restriction endonucleases 
EcoRI and BamHI.  
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Untagged versions of the above plasmids for mammalian expression were created by 
subcloning human and canine SOD1 constructs into pCI-NEO (Promega) with a forward 
primer containing an EcoRI site and a Kozak sequence and a reverse primer containing 
a NotI site. For cSOD1, the primers were 5’-
agtcgaattcgccaccATGGAGATGAAGGCCGTGTGC-3’ and 5’-
atcggcggccgcTTATTGGGCGATCCCAATGACA-3’. For hSOD1, the primers were 5’-
agtcgaattcgccaccATGGCGACGAAGGCCGTG-3’ and 5’-
atcggcggccgcTTATTGGGCGATCCCAATTACACC-3’. Positive clones were verified by 
sequencing. 
Cell Culture, Transfection, and Microscopy 
NSC34 cells were grown in DMEM containing 10% fetal bovine serum with 10 
U/mL penicillin and 10 µg/mL streptomycin. Cells were split into 12-well plates at 5X105 
cells/well 18 hours prior to transfection with media lacking antibiotics. Cells were 
transiently transfected with 900 ng of midi-prep DNA (Promega) and 6 µL Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol. Twenty-four hours later, 
cells were split into 24-well plates at varying densities for microscopy, with a small 
aliquot taken for protein analysis. Forty-eight hours after transfection, cells were washed 
once with phosphate buffered saline (PBS) and fixed in 4% paraformaldehyde for 30 
minutes at room temperature, followed by three PBS washes. Cells were counterstained 
with DAPI in PBS containing 0.1% Triton X-100 for 10 minutes, followed by three PBS 
washes. Images were captured on a Nikon Eclipse TE300 inverted microscope using 
Metamorph software (Molecular Devices). Observers were blinded during cell counts, 
and at least 120 cells were counted for each condition in three separate experiments.  
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Recombinant SOD1 Production 
Rosetta 2 E. coli (Novagen) containing GST-tagged cSOD1 WT, E40K, and 
T18S and hSOD1 WT, G85R, or E40K in pGEX4T-1 were grown in LB media with 100 
µg/mL ampicillin and 25 µg/mL chloramphenicol at 37°C overnight, then diluted 1:10 in 
pre-heated LB with antibiotics and grown for two hours at 37°C. Protein production was 
induced for a further four hours after the addition of 1.0 mM IPTG. Cells were pelleted 
by centrifugation at 3500xg for 25 minutes, washed with 1X PBS, centrifuged again, and 
frozen until needed for purification. 
Cell pellets were thawed on ice and resuspended in lysis buffer (10 mM Tris, 1 
mM EDTA, 150 mM NaCl, 1% Triton X-100, 5 mM DTT, pH 8.0). Cells were incubated 
with 4 mg/mL lysozyme (Sigma) for 15 minutes at room temperature, followed by 
sonication and centrifugation at 10,000xg for 15 minutes. 600 µL of a 50% slurry of pre-
equilibrated glutathione sepharose 4B beads (GE Healthcare) was then added to each 
supernatant and incubated with end-over-end rotation for 18 hours at 4°C. Beads were 
then washed three times with PBS and the bound SOD1 proteins cleaved from GST 
with the Thrombin Cleavage Capture Kit (Novagen) as per manufacturer’s instructions. 
SOD1 proteins were metallated by dialysis against 100 mM Tris (pH 8.0), 300 mM NaCl, 
and 200 µM CuCl2 for 3.5 hours, followed by dialysis against 100 mM Tris, 300 mM 
NaCl, and 200 µM ZnCl2 for 3.5 hours as previously described (Chia et al 2010). 
Metallated proteins were then dialyzed overnight at 4°C against 20 mM Tris (pH 7.8), 10 
mM NaCl, and concentrated using Amicon Ultra centrifugal filters with a 10K membrane. 
SOD1 concentrations were determined using the Bradford assay. 
 
	
	
54	
SOD1 Dismutase Activity Assay 
SOD1 enzymatic activity was determined using the SOD Determination Kit 
(Sigma) according to manufacturer’s protocol. Recombinant cSOD1 WT, E40K, T18S 
and hSOD1 WT, G85R, and E40K were diluted to 50 ng/µL with 20 mM Tris (pH 7.8), 
10 mM NaCl, then 10-fold serially diluted down to 50 pg/µL. SOD1 from bovine 
erythrocytes (Sigma) was used to generate a standard curve from 0.1 U/mL to 50 U/mL. 
The assay was performed a total of three times. 
 
Denaturing and Partially Denaturing SDS-PAGE and Immunoblotting 
For denaturing gels, boiled samples were run on a 14% acrylamide Tris gel and 
transferred to nitrocellulose membranes. Membranes were blocked in PBS with 0.05% 
Tween (PBS-T) containing 5% milk for 1 hour at room temperature and incubated with 
anti-SOD1 (FL-154) antibody (Santa Cruz) in 5% milk PBS-T overnight at 4°C. 
Following three washes, membranes were incubated with donkey anti-rabbit IgG, 
horseradish peroxidase-linked whole antibody (GE Healthcare) at 1:5000 in 5% milk 
PBS-T for 2 hours at room temperature. Blots were developed with ECL 2 Western 
Blotting Substance (Pierce) and visualized on a G:Box Chemi XT4 imager (Syngene). 
Unless otherwise indicated, Western blots were repeated twice. 
Partially denaturing PAGE was performed as previous described (Tiwari & 
Hayward 2003). Briefly, 1 µg of recombinant cSOD1 WT, E40K, T18S and hSOD1 WT 
and G85R were mixed with partially denaturing sample buffer without a reducing agent 
(62 mM Tris, 10% glycerol, 0.05% bromophenol blue, 0.4% SDS, pH 6.8) and incubated 
at 37°C for 30 minutes. Samples were then run on a 14% acrylamide Tris gel (both the 
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gel and the running buffer contained 0.1% SDS) and stained with Gel Code Blue 
(Pierce) according to the manufacturer’s protocol. This protocol was repeated for 
recombinant hSOD1 E40K. The experiments were repeated once with a fresh 
preparation of recombinant canine SOD1. 
 
Filter Trap Assay 
For TFE-treated recombinant protein, 2 µg of recombinant cSOD1 WT, E40K, 
and T18S were incubated in 0%, 10%, and 20% trifluoroethanol (TFE) for 6 hours at 
37°C with agitation. Samples were then dialyzed against 20 mM Tris (pH 7.8), 10 mM 
NaCl overnight at 4°C. For untagged human and canine SOD1 constructs expressed in 
NSC34 cells, cells were washed once in PBS, collected, and lysed via sonication in 
PBS containing protease inhibitors. Samples were spun at 800xg for 10 minutes to 
remove large cell debris without removing SOD1 aggregates. Protein concentration was 
determined via Bradford assay and adjusted to 1 µg/µL. The dialyzed TFE-treated 
recombinant SOD1 proteins or 150 µg of cell lysate were then run over a 0.2 µM 
cellulose acetate membrane on a Minifold II Slot Blot System (Whatman) and washed 
once with PBS. Membranes were blocked in 5% milk PBS-T for 1 hour at room 
temperature and incubated with anti-SOD1 (FL-154) antibody (Santa Cruz) in 5% milk 
PBS-T overnight at 4°C. Following three washes, membranes were incubated with 
donkey anti-rabbit IgG, horseradish peroxidase-linked whole antibody (GE Healthcare) 
at 1:5000 in 5% milk PBS-T for 2 hours at room temperature. Blots were developed with 
ECL 2 Western Blotting Substance (Pierce) and visualized on a G:Box Chemi XT4 
imager (Syngene). Experiments were repeated a total of three times. 
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RESULTS 
Spinal cords of DM dogs contain detergent-insoluble mutant SOD1 that increases 
with disease severity 
The presence of detergent-insoluble mutant SOD1 species in spinal cords of 
SOD1 transgenic mice and patients with SOD1 A4V mutations has been well 
characterized (Deng et al 2006; Wang et al 2003). To determine if this biochemical 
property was also found in DM, we fractionated spinal cords from two non-affected dogs 
and four homozygous SOD1 E40K dogs with DM of increasing disease grade (See 
(Shelton et al 2012) for details on DM grade) into detergent-soluble (designated S1) and 
–insoluble (designated P2) fractions. We included non-affected dogs of different ages to 
control for age-related SOD1 accumulation, which has been shown in SOD1 WT 
transgenic mouse and rat models, as many dogs with Grade 3 and 4 DM are >14 years 
old (Prudencio et al 2009a). Spinal cords from transgenic rats overexpressing SOD1 
WT or G93A were used as controls. Western blot analysis revealed the presence of 
detergent-insoluble SOD1 in DM-affected dog spinal cords that increased with disease 
severity, despite approximately identical levels of detergent-soluble SOD1 between 
control and DM-affected dogs (Figure 1). As expected, a small amount of detergent-
insoluble WT cSOD1 was found in the older non-affected spinal cord, but this level was 
below that of even Grade 1 DM. While advanced age may result in some degree of 
detergent-insoluble SOD1 accumulation in canine spinal cords, it does not account for 
the significant increase seen in DM-affected spinal cords. Thus, we conclude that the 
E40K mutation shares the same accumulation of detergent-insoluble aggregates as 
seen in human ALS and rodent models. 
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FIGURE 1. Canine DM spinal cords contain detergent-insoluble SOD1 that 
correlates with disease severity. Detergent extraction of cSOD1 from thoracic spinal 
cord sections of non-affected dogs (Ctrl) and DM-affected dogs of increasing disease 
severity (Grades 1-4, with Grade 1 mild and Grade 4 severe) show increasing levels of 
detergent-insoluble mutant SOD1 (P2 fraction) with increasing DM Grade. Age is 
indicated in parentheses. As controls, transgenic rats overexpressing hSOD1 WT or 
SOD1 G93A were included. The S1 lanes contain 16 µg protein, except for the 
transgenic rat samples at 4 µg, and the P2 lanes contain 18.6 µg protein. 
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Properties of canine SOD1 mutations 
To date, only two mutations in cSOD1 have been described in the literature, as 
compared to the >120 mutations known for hSOD1 (Awano et al 2009; Wininger et al 
2011). The sequence for cSOD1 was originally determined from a study looking for 
mutations in dogs with a form of spinal muscular atrophy and is hypothesized to contain 
eight beta sheets and a metal-binding active site similar to its human counterpart 
(Green et al 2002). As can be seen from the primary amino acid sequence, the E40K 
mutation falls within connecting loop III and results in a +2 charge shift, while the T18S 
mutation occurs in the second beta strand and does not change overall protein charge 
(Figure 2). Both mutations result in minor changes in hydrophobicity. Such varying 
characteristics reflect the inconsistencies seen in trying to correlate protein charge, 
hydrophobicity, and even aggregation propensity to disease onset and progression in 
familial ALS (Prudencio et al 2009b). As neither canine mutation disrupts the metal 
binding region of the enzyme, we predicted that both mutations retain dismutase 
activity, which lends credibility to a gain of toxic function and not loss of function in the 
dog model where a majority of dogs homozygous for mutant SOD1 show the DM 
phenotype.  
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FIGURE 2. Canine SOD1 primary sequence and known SOD1 mutations. (A) 
Similar to hSOD1, cSOD1 contains 8 beta sheets interspersed by connecting loops and 
surrounding an active site that binds copper. Known cSOD1 mutations are depicted in 
red below the primary sequence. (B) Location, Δcharge, and Δhydrophobicity for known 
cSOD1 mutations. Δcharge calculation performed with PROTEIN CALCULATOR v3.3 
(Scripps). Δhydrophobicity calculated according to (Chiti et al 2003).  
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To measure enzymatic activity, a commercially available superoxide dismutase 
activity kit was used with recombinant cSOD1 WT, E40K, and T18S proteins. As 
controls, we compared dismutase activity with recombinant hSOD1 WT and G85R, a 
metal binding region mutant with significantly reduced activity (Borchelt et al 1994). As 
predicted from the structural location of these mutants (i.e. outside of the metal binding 
region), both cSOD1 mutants retain full enzymatic activity (Figure 3A), providing 
evidence in favor of a toxic gain of function in dogs homozygous for these mutations.  
Since both canine mutants were dismutase active, we predicted that they would 
remain as structural dimers under partially denaturing polyacrylamide gel 
electrophoresis as consistent with previous reports of human mutations (Tiwari & 
Hayward 2003). Using a lower SDS concentration (0.4%) and no reducing agent or 
boiling, this prediction was confirmed (Figure 3B). Both the E40K and T18S cSOD1 
mutants migrated predominantly as dimers, while the hSOD1 G85R mutant migrated 
mostly as a monomer, reflecting its well documented monomeric state.(Zetterstrom et al 
2007) The shifted position of the E40K mutant on the gel reflects its +2 charge shift as 
compared to the WT or T18S proteins (Figure 2B).  This is in agreement with our data 
reflecting full enzymatic activity in these mutants indicating the existence of a functional 
dimer. Thus, our data confirm that both cSOD1 mutants form enzymatically active 
dimers and, more importantly, that affected dogs homozygous for either mutant do not 
experience a loss of dismutase activity. 
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FIGURE 3. Canine SOD1 mutants form enzymatically active dimers. (A) Dismutase 
activity assay performed on recombinant canine and human SOD1 proteins. No 
significant difference between cSOD1 WT and E40K or T18S. * p<0.05 (B) Partially 
denaturating PAGE gel showing that cSOD1 WT, E40K, and T18S predominantly 
migrate as dimers, while the metal binding hSOD1 mutant G85R exists as a monomer. 
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Canine SOD1 mutations are unstable and prone to aggregation 
As has been confirmed with hSOD1 mutants, we hypothesized that mutations in 
the cSOD1 protein would result in reduced stability and increased aggregation potential 
(Münch & Bertolotti 2010). We observed that treatment of the canine mutants, but not 
WT, with 20% TFE resulted in significant aggregation as detected by filter trap assay, 
indicating that the E40K and T18S mutants more readily expose their hydrophobic 
surfaces and aggregate than WT (Figure 4). Also, at lower concentrations of TFE, not 
only do both E40K and T18S show greater signal on the filter trap assay than WT, but 
E40K shows the most signal at 0% TFE indicating that it is relatively more unstable than 
T18S. This increased aggregation signal correlates with its greater degree of 
aggregation in cell culture (Figure 5A).  
To visualize the degree of aggregation of cSOD1 mutants, we tagged WT, E40K, 
and T18S with an N-terminal YFP tag and transiently transfected each construct into 
NSC34 cells, an immortalized motor neuron-like cell line (Cashman et al 1992). After 48 
hours, similar expression levels resulted in significant aggregation in 10-20% of cells for 
both mutants, while the WT protein remained soluble (Figure 5). Data show that the 
degree of aggregation for the E40K mutant was significantly more than the T18S 
mutant, which reflects its increased aggregation as seen by filter trap assay. The 
aggregates closely resemble SOD1 aggregates for hSOD1 proteins in cell culture 
(Gomes et al 2010). 
	
	
63	
 
 
 
 
 
 
 
 
FIGURE 4. Canine SOD1 mutants are prone to aggregation in vitro. Filter trap 
assay of recombinant cSOD1 proteins exposed to increasing concentrations of TFE. 
The E40K and T18S mutants show heightened sensitivity to 20% TFE compared to WT, 
indicating an increased ability to aggregate. 
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FIGURE 5. Canine SOD1 mutants aggregate in cell culture. (A) NSC34 cells 
transiently transfected for 48 hours with 900 ng of YFP-tagged cSOD1 WT, E40K, or 
T18S. Scale bar = 20 µm. (B) Quantification of A. At least 120 cells were counted in 
three separate experiments. * p<0.05; ** p<0.01 (C) Western blot of transfected NSC34 
cell lysates (17.6 µg initial protein with 1:5 serial dilutions) probed with α-SOD1 (FL154) 
or α-GAPDH antibodies. YFP-cSOD1 and the endogenous mouse SOD1 (mSOD1) at 
17 kDa are indicated on the blot. 
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The E40K mutation in hSOD1 fails to recapitulate the aggregation seen in the 
canine mutant 
Since human and canine SOD1 share 79.1% identity, and since >160 mutations 
have been described for the human protein, it was no surprise that the canine E40K 
mutation occurred at a residue shared with hSOD1. In fact, an older review of SOD1 
mutants points out the existence of an E40G mutation, but no primary description exists 
(Turner & Talbot 2008). To address any biochemical overlap between this mutation in 
humans and dogs, we created the E40K mutation in hSOD1 via site directed 
mutagenesis. As the location of this mutation in both human and canine SOD1 falls 
within one of the connecting loops and does not interfere with metal binding, we 
predicted that the human E40K mutant would, like its canine counterpart, be an 
enzymatically active dimer. A partially denaturing PAGE gel and dismutase activity 
confirm these predictions (Figure 6A, 6B). However, when we transiently transfected 
human SOD1 E40K into NSC34 cells, no aggregates were observed, even up to 72 
hours after transfection (Figure 6C and data not shown). This is despite ample YFP-
cSOD1 protein production in cells by Western blot (Figure 6D). To rule out any inhibitory 
effects that the YFP tag may have on aggregation, we transiently-transfected untagged 
hSOD1 WT, G85R, and E40K, as well as cSOD1 WT, E40K, and T18S, into NSC34 
cells and looked for the presence of aggregates via a filter trap assay (Figure 6E). In 
agreement with previous observations with YFP-tagged SOD1 constructs, we found a 
significant aggregation signal from canine E40K and T18S and human G85R, but not 
human E40K. We subsequently created the hSOD1 E40G mutation to see if the lack of 
aggregation in human E40K was amino acid specific, but also found no aggregation in 
NSC34 or HEK293 cells (data not shown). Thus, despite the high sequence similarity 
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between species, the aggregation propensity of the E40K mutation is unique to cSOD1 
under the conditions and with the cell types studied here. 
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FIGURE 6. The human E40K mutation is a dismutase active dimer that fails to 
aggregate. (A) Partially denaturing PAGE gel showing that hSOD1 E40K migrates as a 
dimer with a positive charge shift. (B) Dismutase assay of hSOD1 WT, E40K, and G85R 
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mutations. No significant difference is seen between WT and E40K. (C) Representative 
images of NSC34 cells transiently transfection with 900 ng of YFP-tagged hSOD1 WT 
and E40K showing diffuse cytoplasmic and nuclear distribution with no aggregates. 
Scale bar = 20 µm (D) Western blot of transfected NSC34 cell lysates from C (1:5 serial 
dilutions) probed with α-SOD1 (FL154) or α-GAPDH antibodies. YFP-hSOD1 and the 
endogenous mouse SOD1 (mSOD1) at 17 kDa are indicated on the blot. (E) Filter trap 
assay of NSC34 cell lysates transiently transfected with human or canine SOD1 
constructs lacking the N-terminal YFP tag confirm that hSOD1 E40K does not form 
aggregates.  
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DISCUSSION 
The discovery that mutations in SOD1 are linked to canine DM opens many 
avenues for comparative studies between this disorder and human ALS, as well as a 
multitude of questions on the degree of similarity between these phylogenetically 
separated proteins. An important starting point for comparing the two disorders is 
understanding the biochemical characteristics of the only two known cSOD1 mutations 
linked to this disease as compared to hSOD1. Our results confirm that, like hSOD1 
mutants, mutant cSOD1 forms detergent-insoluble aggregates in spinal cords of 
affected dogs that increase with disease severity. Further data show that both E40K and 
T18S mutations in cSOD1 are not loss of function mutations, but form enzymatically 
active dimers that are prone to aggregation in vitro. Finally, despite a high degree of 
sequence similarity to hSOD1, we show that the aggregation propensity of the 
conserved E40K mutation is unique to cSOD1.  
One of the most striking differences between canine DM and human ALS is that, 
unlike the well documented toxic gain of function in dominantly-inherited SOD1-
mediated human ALS, homozygosity at the SOD1 locus is frequently observed in most 
cases of canine DM (Awano et al 2009; Wininger et al 2011). Thus, unlike the 
heterozygous state found in the majority of ALS patients, a loss of function contributing 
to disease in these animals was a real possibility. In fact, SOD1 knock-out mice display 
mild age-related muscle denervation and degeneration that, depending on the genetic 
background, translate into impaired performance on motor tests (Flood et al 1999; 
Kostrominova 2010; Muller et al 2006; Shefner et al 1999). Therefore, we first needed to 
rule out SOD1 loss of function in these animals. As our data show that the canine E40K 
and T18S mutations form enzymatically active dimers, we are confident that the canine 
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DM model reflects the same toxic gain of function phenotype described for hSOD1 
mutants. However, if it is true that a DM phenotype is most common in the presence of 
two copies of mutant SOD1, and if the >160 mutations in hSOD1 foreshadow the 
possibility of additional mutations in cSOD1 that render it enzymatically inactive, then an 
overlapping DM and SOD1 knock-out phenotype in dogs with such mutation remains an 
interesting possibility. 
In hSOD1, one common feature among all mutants is increased aggregation 
propensity in vitro and in vivo. This is accompanied by decreased protein stability as 
measured by differential scanning fluoroscopy, susceptibility of many, but not all, 
mutants to proteinase K digestion, and abnormal migration under reducing conditions 
when compared to the remarkably stable WT protein (Münch & Bertolotti 2010; 
Ratovitski et al 1999; Tiwari & Hayward 2003). Our results with cSOD1 confirm that the 
E40K and T18S mutations are no exception. We consistently observed SOD1 
aggregates in transiently-transfected NSC34 cells that, in our eyes, exceeded the 
degree of aggregation for many human SOD1 mutants. Coupled with its increased 
aggregation in the presence of TFE and the accumulation of detergent-insoluble SOD1 
species in cases of canine DM, cSOD1 mirrors many of the properties of its human 
counterpart, and is predicted to recapitulate additional properties. However, the slight 
differences between the clinical presentations in canine DM and human ALS may reflect 
significant differences between the two proteins. For example, it has been shown that 
mutant hSOD1 aggregates possess prion-like properties in their ability to accelerate the 
misfolding and aggregation of additional SOD1 in vitro, as well as physically enter cells 
and cause the misfolding and aggregation of intracellular mutant and WT SOD1 (Chia et 
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al 2010; Grad et al 2011; Munch et al 2011). With SOD1 playing a role in canine DM, 
does this same mechanism hold true in dogs? One group elegantly elucidated the 
importance of the W32 residue in hSOD1 in maintaining species-specific cross-seeding 
of misfolded SOD1 (Grad et al 2011) As cSOD1 lacks this critical residue, does this 
impact its ability to seed? These questions highlight the significance that canine DM 
offers as an additional tool to pursue disease mechanisms of SOD1.  
Canine and human SOD1 share approximately 80% identity. While the T18S 
mutation occurs at a unique amino acid found only in cSOD1, the E40K mutation occurs 
at a conserved residue between canine and human SOD1. When we created the E40K 
mutation in hSOD1 to explore the similarities with the canine mutant, we showed that 
this mutation, like canine E40K, is a dismutase active dimer. However, we were 
surprised to find that mutating this residue in hSOD1 does not result in an aggregation 
phenotype despite the prevalent aggregation seen in its canine counterpart and despite 
the appearance of an hSOD1 E40G mutation in the SOD1 literature (Turner & Talbot 
2008). We also did not observe aggregation when we transiently transfected YFP-
hSOD1 E40G into NSC34 cells (data not shown). The most recent edition of the online 
ALSod database (http://alsod.iop.kcl.ac.uk/, accessed February 22nd, 2013) no longer 
lists the hSOD1 E40G mutation, and no primary literature source exists, thus E40G may 
not represent a disease causing mutation in humans.  As over 160 causative mutations 
spanning over 70 residues have been identified for hSOD1, the discovery of a mutation 
that causes aggregation in a species-specific manner is unique and raises interesting 
questions concerning the relationship between protein sequence, tertiary structure, and 
aggregation propensity. Perhaps hSOD1 contains a sufficiently different tertiary 
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structure that ameliorates the instability conferred by E40K. Or perhaps the structure of 
cSOD1 renders mutations at this residue particularly unstable.  
What are the implications of another animal model of ALS, and what are the 
advantages of the canine DM model as compared to existing SOD1 models? Canine 
DM is not a perfect model of human ALS (Table 1). So far, a majority of dogs 
homozygous for SOD1 mutations develop disease, although some heterozygous dogs 
do develop canine DM and show intermediate levels of SOD1 aggregates in motor 
neurons (Joan Coates, personal communication). Additionally, the motor neuron loss 
that is the hallmark of human ALS is not seen to the same degree histopathologically 
and DM also involves proprioceptive pathways (Table 1) (Awano et al 2009; Coates et 
al 2007; Coates & Wininger 2010; Shelton et al 2012). Despite these differences, canine 
DM offers a naturally occurring, non-artificial system in which to study SOD1 and ALS. 
This differs from many of the mouse and rat transgenic models created so far, many of 
which require hSOD1 overexpression to non-physiological levels (e.g. G93A). In 
contrast, dogs with canine DM develop disease late in life with physiological levels of 
mutant cSOD1, thus providing a better picture of the natural disease progression. Our 
results show that, at the biochemical level, canine and human SOD1 are remarkably 
similar. Both aggregate readily when mutated, both display decreased protein stability, 
and both contain mutants that are functionally indistinct from WT protein (Table 1). 
Thus, it is reasonable to assume that human and canine SOD1 cause disease via a 
similar mechanism. In elucidating biochemical similarities between human ALS and 
canine DM, this study expands the research toolkit for understanding ALS and opens 
the door for developing novel therapies for ALS. 
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TABLE 1. Clinical, genetic, pathological, and biochemical differences between 
human ALS and canine DM.  
a(Deng et al 2006; Wang et al 2003) b(Münch & Bertolotti 2010) c(Gomes et al 2010; 
Matsumoto et al 2005) *This study 
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ABSTRACT 
RNA targeted therapeutic strategies are being developed for neurodegenerative 
syndromes. Protein levels change as a function of protein half-life (t1/2), critically 
influencing the timing and application of therapeutics. Protein kinetics and concentration 
may also play important roles in neurodegeneration. Thus, it is essential to understand 
in vivo protein kinetics including half-life. Using a stable isotope labeling technique 
combined with mass spectrometric detection, we determined the kinetics of superoxide 
dismutase 1 (SOD1), a protein that causes amyotrophic lateral sclerosis (ALS), in vivo. 
Application of this method to rats expressing human SOD1 demonstrated that SOD1 is 
a long-lived protein, that the t1/2 of SOD1 in the CSF is similar to its t1/2 in the CNS, and 
that SOD1 t1/2 is longest in the CNS when compared to other tissues. Translation of this 
method to humans demonstrated successful label incorporation in the CSF and 
confirmed that SOD1 is a long-lived protein in the CSF of healthy subjects (t1/2 25 ± 7 
days). The findings from this study provide important insights into the kinetics of SOD1 
and can be translated into the design and implementation of clinical trials that target 
long-lived CNS proteins.  
 
	
	
82	
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder 
characterized by the loss of motor neurons in the spinal cord and cortex, resulting in 
progressive paralysis and death on average 2-3 years after symptom onset (Kiernan et 
al 2011). With an incidence of 1.5 - 2.7 cases per 100,000 in North America and 
Western Europe, ALS is the third most common neurodegenerative disorder after 
Alzheimer’s and Parkinson’s diseases and the most common motor neuron disease 
(Worms 2001). Almost universally fatal, the only FDA-approved treatment is Riluzole, a 
non-specific NMDA receptor antagonist that prolongs survival by 2-4 months (Cheah et 
al 2010). Moving forward, therapies that specifically target the proteins responsible for 
familial forms of ALS are being developed. For these and other targeted therapies in 
neurodegenerative disease, quantification of protein kinetics (t1/2, production, and 
clearance) is a key factor in optimizing the frequency of delivery and determining the 
optimal time to assess for a biological response. 
Measuring protein turnover has been routinely conducted in cell culture with 
radioisotopes that have provided important information regarding how protein 
characteristics (mutations, conformations, and post-translational modifications among 
others) affect protein turnover. However, measuring turnover rates of proteins in an 
immortalized, rapidly dividing cell culture model has limitations and shows discrepancies 
when turnover rates of identical proteins are compared between tissues and cell culture 
models (Price et al 2010). The development of stable isotope labeling kinetics (SILK) 
has enabled the study of protein turnover rates in vivo using a safe, stable isotope 
amino acid tracer that is incorporated into newly synthesized proteins and can be 
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quantitatively measured by mass spectrometry – a technique that has been highly 
successful in studies of amyloid-beta in human CSF and animal model brain (Bateman 
et al 2007, Bateman et al 2006, Bateman et al 2009, Castellano et al 2011, Elbert et al 
2008, Mawuenyega et al 2013, Mawuenyega et al 2010, Potter et al 2013). In these 
studies a relatively short (9 hour) intravenous infusion of the stable isotope 13C6-leucine 
resulted in adequate labeling of the rapidly turned over amyloid-beta (t1/2 of 8 hours). 
However, the ability to measure the turnover of long-lived proteins is challenging, 
especially in humans. The labeling time needed becomes too long for an intravenous 
approach, and sample collection must be carried out over many days instead of hours. 
Indeed, D2O-labeling studies in both animal models and human subjects have 
demonstrated that long-term labeling is necessary to measure proteins with a t1/2 on the 
order of days (Fanara et al 2012, Price et al 2012). Here, we report the development of 
a SILK method using a stable isotope labeled amino acid to measure the turnover of a 
long-lived protein in rodents and in human CSF.  
We applied our SILK method first to SOD1, a homodimeric metalloenzyme that 
catalyzes the conversion of superoxide anion to hydrogen peroxide and molecular 
oxygen (McCord & Fridovich 1969, Rosen et al 1993). Mutations in SOD1 cause 
dominantly inherited ALS via a toxic gain of function. Recent work by our group using 
antisense oligonucleotides (ASOs) against superoxide dismutase 1 (SOD1), a gene 
responsible for 20% of familial ALS cases, has shown great promise in animal models 
and has recently completed a Phase I clinical trial (Miller et al 2013). Our work and 
other targeted therapies highlight the need to understand SOD1 kinetics in order to 
effectively design clinical trials (Foust et al 2013, Gros-Louis et al 2010, Liu et al 2012, 
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Miller et al 2013, Wang et al 2014). Specifically, t1/2 determines the predicted nadir for 
SOD1 levels in the CSF of patients treated with protein production inhibitors. Since 
SOD1 CSF levels correlate with SOD1 levels in the CNS, measurement of SOD1 CSF 
protein in humans offers the ability to determine pharmacodynamics for future clinical 
trial design (Winer et al 2013). We first developed our SILK method in rats expressing 
human SOD1 protein, from which we successfully measured the t1/2 of SOD1 in tissues 
and in the CSF. Translating our findings in rats to human CSF demonstrated excellent 
labeling of SOD1, defined the t1/2 of SOD1 in humans, and further validated this method 
for using stable isotopes to measure turnover of long-lived proteins. 
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METHODS 
Stable Isotope Labeling in Rats 
13C6-leucine labeling experiments were performed in 100-day-old male and 
female transgenic rats overexpressing human SOD1 WT or SOD1 G93A (Chan et al 
1998, Nagai et al 2001). Animal protocols were approved by the Institutional Animal 
Care and Use Committee (IACUC) at Washington University and conducted according 
to the NIH Guide for Care and Use of Laboratory Animals. Both labeled L-leucine (U-
13C6, 97-99%, CLM-2262) and unlabeled L-leucine (ULM-8203) were obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, MA) and dissolved in water (5 mg/mL). 
To increase palatability, leucine solutions were sweetened with sucrose (20 mg/mL). 
During the course of the experiment, rats were fed ad libitum a modified Baker Amino 
Acid diet chow that contained no leucine (TestDiet). 50 mg of leucine (10 mL total 
volume) was orally administered twice daily (100 mg total daily dose) in accordance with 
published daily leucine requirements (Owens et al 1994). Before administration of the 
13C6-leucine label, rats were acclimated to the unlabeled leucine diet for 1-2 weeks. 
Rats were then labeled with 13C6-leucine for 7 days and chased with unlabeled leucine 
for an additional 7, 19, 25, or 56 days. At the indicated time points, rats were 
anesthetized with isoflurane and approximately 200 µL of CSF was extracted from the 
cisterna magna, flash frozen, and stored at -80°C. Rats were then perfused (15 mL/min) 
with cold PBS containing 0.03% heparin sulfate for 15 minutes. Blood was collected 
from the mechanically ruptured vena cavae at the start of perfusion, spun at 1800xg for 
10 minutes, and the supernatant flash frozen and stored at -80°C. After perfusion, spinal 
cord, cortex, liver, and kidney were harvested, flash frozen in liquid nitrogen, and stored 
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at -80°C. Three rats were sacrificed at each collection time point with the following 
exceptions: SOD1 WT Days 3 and 7 (n=6), SOD1 G93A Day 14 (n=2). 
Fractionation of Tissue Lysates 
Tissues were thawed on ice and homogenized in 5x v/w of TEN buffer (10 mM 
Tris, pH 8, 1 mM EDTA, 100 mM NaCl) containing the protease inhibitors 
AEBSF, aprotinin, bestatin E-64, leupeptin, and pepstain A (Sigma P8340). A portion 
of the tissue lysate was centrifuged at 100,000xg for 10 minutes (Beckman-Coulter 
Optima TLX-120 Ultracentrifuge) and the supernatant saved for misfolded SOD1 
immunoprecipitation. Detergent-soluble SOD1 was extracted as described previously 
(Prudencio et al 2010). Briefly, the homogenate was mixed with an equal volume of 2X 
Extraction Buffer (10 mM Tris, pH 8, 1 mM EDTA, 100 mM NaCl, 1% NP-40, protease 
inhibitors), sonicated, and centrifuged at 100,000xg for 10 minutes at 4°C. The 
supernatant, representing the detergent soluble fraction, was transferred to a new tube 
and protein concentration was determined by BCA assay (Pierce).  
 
Preparation of 13C6-leucine labeled SOD1 standard curve 
 Labeled (containing 13C6-leucine) and unlabeled media were prepared from 
RPMI-1640 medium without arginine, leucine, lysine, and phenol red (Sigma R-1780) 
supplemented with 10% dialyzed fetal bovine serum (Sigma F0392), 200 mg/L L-
arginine, 40 mg/L lysine, and 50 mg/L of either 13C6-leucine (labeled) or unlabeled 
leucine. HEK293T cells, which constitutively express human SOD1, were used to 
prepare 13C6-leucine labeled SOD1 standards. Cells were grown to near confluence in 
complete RPMI-1640 medium supplemented with 10% fetal bovine serum, then split 
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into 10-cm dishes at a low concentration and allowed to settle overnight. Cells were 
then washed once with PBS and grown to near confluence (approximately 72 hours) in 
0%, 0.08%, 0.17%, 0.34%, 0.68%, 1.25%, 2.5%, 5%, 10%, or 20% labeled/unlabeled 
media. Cells were then washed once with PBS and homogenized in cold lysis buffer (50 
mM Tris pH 8, 150 mM NaCl, 1% NP-40, protease inhibitors) with sonication (20% 
power for 20 seconds). The lysate was spun at 15,000xg for 5 minutes, the supernatant 
collected, and protein quantified using the BCA Protein Assay (Pierce). Aliquots of 
lysate were frozen at -80°C. 
 
Isolation and mass spectrometric analysis of 13C6-leucine labeled SOD1, plasma 
free 13C6-leucine, and 13C6-leucine labeled total protein 
M-270 Epoxy Dynabeads (Invitrogen) were crosslinked to either anti-SOD1 
(mouse monoclonal; Sigma S2147) or anti-misfolded SOD1 (B8H10, mouse 
monoclonal, MM-0070 MédiMabs) antibodies using the Dynabeads Antibody Coupling 
Kit (Invitrogen) at a concentration of 25 µg antibody per mg of beads. Total soluble 
SOD1 was immunoprecipitated from the detergent soluble tissue fraction or standard 
curve HEK293T cell lysate (approximately 100 µg of protein) using 50 µL of α–SOD1 
crosslinked Dynabeads overnight in 1X TEN buffer containing 0.1% Tween and 
protease inhibitors. Misfolded SOD1 was immunoprecipitated from tissue lysates taken 
prior to detergent fractionation, which had been spun at 100,000xg. The beads were 
washed three times in PBS and SOD1 was eluted from the beads with 50 µL of formic 
acid. The formic acid eluent was transferred to a new polypropylene tube and 
lyophilized via speed vacuum (Labconco CentriVap), resuspended with 100% methanol, 
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lyophilized again via speed vacuum, and resuspended in 25 µL of 25 mM NaHCO3 
buffer (pH 8.8). 600 ng of sequencing grade endoproteinase Glu-C (Roche) was added 
to each sample and digestion allowed to proceed at 25°C for 17 hours. Samples were 
again lyophilized via vacuum and resuspended in 20 µL of 5% acetonitrile/0.05% formic 
acid prior to liquid chromatography-triple quadrupole-mass spectrometry (UPLC/tandem 
MS) analysis (Xevo, Waters). The 13C6-leucine/12C6-leucine ratio in SOD1 peptides was 
quantified by comparing the area under the curve for the SOD1 peptides 
KADDLGKGGNEE, GLHGFHVHE, and SNGPVKVWGSIKGLTE in the presence or 
absence of 13C6-leucine. The full list of transition ions used to acquire the UPLC/tandem 
MS data is listed in Supplemental Table 1. Excellent correlations between these 
peptides enabled us to use the peptide with the most robust signal for kinetic analysis 
(Supplemental Figure 3). 
Plasma free 13C6-leucine abundance reflected the precursor pool enrichment for 
SOD1 protein synthesis. Plasma proteins were precipitated with 10% trichloroacetic 
acid overnight at 4°C, the protein pellet retained for quantification of bound 13C6-leucine, 
and the supernatant removed after centrifugation at 21,000xg for 10 minutes. The 
supernatant was chemically derivatized to form the N-heptafluorobutyryl n-propyl esters 
of plasma-free amino acids, and 13C6-leucine enrichment was quantified using capillary 
gas chromatography-negative chemical ionization-quadrupole mass spectrometry (GC-
MS; Agilent 6890N Gas Chromatograph and Agilent 5973N Mass Selective Detecter) 
with the m/z of 355 as compared to 349 as described previously (Potter et al 2013, 
Reeds et al 2006). Protein bound 13C6-leucine abundance was quantified in the TCA 
precipitated-proteins after sonicating the pellet in a cold 10% TCA solution, twice. The 
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pellets were hydrolyzed in 6 N HCl for 24 hours at 110°C. The hydrolysates were 
subjected to cation-exchange chromatography (50W-X8 resin, Sigma) to trap the 
protein bound amino acids that were eluted from the column with 6N NH4OH. The 
samples were then dried under vacuum and processed for GC-MS analysis as 
described previously (Parise et al 2001). Labeled/unlabeled ratios from both the 
UPLC/tandem MS and GC-MS were obtained as tracer:tracee ratios (TTR) and 
converted to mole fraction label (MFL) to account for the bias that occurs at high stable 
tracer enrichments using the equation: 𝑀𝐹𝐿 = %%&'(%%&. 
 
Human subjects 
 Studies involving human subjects were approved by the Washington University 
Human Studies Committee and the Clinical Research Unit (CRU) Advisory Committee 
(an Institute of Clinical and Translational Sciences (ICTS) Resource Unit). Informed 
consent was obtained from all participants. Demographics of the five participants are 
described in Supplemental Table 2. All participants underwent an initial screening visit 
that consisted of a physical and neurological examination and phlebotomy for a 
complete blood count, complete metabolic panel, prothrombin time, and partial 
thromboplastin time. Exclusion criteria included evidence of neurologic disorder by 
history or examination, inability to safely take food and drink by mouth, lab values 
greater than 2x upper limit of normal, special diets (e.g. gluten-free), pregnancy, allergy 
to lidocaine, history of bleeding disorders, or contraindications for lumbar puncture. 
Eligible participants consumed a prepackaged reduced leucine diet supplemented with 
13C6-leucine powder for 10 days. The reduced leucine diet (approximately 2000 mg 
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leucine/day) was prepared by dieticians in the Washington University Research Kitchen, 
handed to the subjects, and consumed at home. Food intake was monitored by a self-
reported food journal. Participants consumed 13C6-leucine (Cambridge Isotope 
Laboratories CLM-2262) after dissolving 330 mg 13C6-leucine in 120 mL of tap water + 
Kool-Aid® flavored powder three times per day (total daily dose = 990 mg). During the 
13C6-leucine labeling period, overnight fasting blood was collected on days 1 and 10 of 
the research meal plan. On day 11, participants resumed consumption of their habitual 
diets. CSF (via lumbar puncture) and venous blood samples were collected 
approximately 14, 28, 42, and 67-84 days after 13C6-leucine labeling was initiated 
(actual time points differed slightly between subjects). Approximately 20-25 mL of CSF 
was drawn with each lumbar puncture. 
Blood was centrifuged at 1800xg for 10 minutes, the serum aliquoted into low-
binding 1.5 mL tubes (Ambion AM12450), frozen on dry ice, and stored at -80°C. CSF 
(20-25 mL) was centrifuged at 1000xg for 10 minutes at 4°C, and 1 mL was aliquoted 
into several low-binding 1.5 mL tubes, frozen on dry ice, and stored at -80°C. 
Immunoprecipitation of SOD1 from 1 mL of CSF was carried out by adding 50 µL of α-
SOD1 cross-linked M-270 Dynabeads, protease inhibitors, Tween (final concentration 
0.1%), and rotating the tubes overnight at 4°C. SOD1 was eluted from the beads (99% 
50 µL formic acid), digested (endoproteinase Glu-C), and prepared for LC/tandem MS 
analysis as described above for rodent CSF. Plasma free 13C6-leucine enrichment was 
quantified as described above, and used to reflect the precursor pool enrichment for 
SOD1 protein synthesis. 13C6-leucine abundance in human plasma (50 µL) and CSF (1 
mL) protein precipitates (10% TCA) was quantified as described above.  
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Compartmental modeling of rodent and human kinetic data 
 Modeling was conducted using SAAM II (Resource for Kinetic Analysis, 
University of Washington, Seattle). For the animal studies, the kinetic data for plasma 
free 13C6-leucine, tissue-specific SOD1 species, and total protein from liver, cortex, and 
spinal cord were incorporated into a compartmental model. The KADDLGKGGNEE 
peptide was used for modeling as it had the most robust LC/tandem MS signal. The 
model consisted of a central plasma leucine compartment that initially received the 
orally administered tracer and which exchanged tracer-labeled leucine with all proteins 
throughout the body (Supplemental Figure 2A,B).  Arrows connecting the compartments 
of the model represent first order rate constants (units: pools day-1) that describe the 
flux of leucine between compartments. The model describes the complete time course 
of tracer incorporation and clearance into each measured compartment; the fractional 
turnover rate (FTR, pools/d) for each compartment is the rate constant for the return of 
leucine from each compartment back to plasma. Note that isotopic enrichment time 
course data was available for plasma leucine and for all protein/tissue compartments 
highlighted in color in Supplemental Figure 2A,B. A “whole body protein” compartment 
was used to account for most of the shape information of plasma leucine as label 
exchanged with all other unsampled proteins. The SAAM program devised first-order 
linear differential equations as dictated by the structure of the model, and optimized the 
fit of the model-projected solution to the data for all sampled protein/tissue 
compartments simultaneously by adjusting the model rate constants through an iterative 
process. The model was set up in SAAM in a manner to simulate the appearance of 
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label into plasma as a result of the twice-daily tracer dosing scheme for the 7 days of 
oral tracer labeling. A similar model was used for the human studies to account for 
plasma free 13C6-leucine, CSF total protein, and CSF SOD1 species for each subject 
following 10 days of thrice-daily oral tracer administration (Supplemental Figure 2C). 
The GLHGFHVHE peptide gave the most robust LC/tandem MS signal for the human in 
vivo tracer kinetics and was therefore used for modeling. Like the animal model, plasma 
leucine comprised the central compartment from which tracer was exchanged with all 
other compartments. t1/2 was calculated as ln 2/FTR.  
 
Statistics 
 Descriptive statistics for variables in each kinetic model described in this 
manuscript (FTR, 95% confidence intervals) were calculated using the SAAM II 
modeling software.  
 
Study approval 
 Animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Washington University and conducted according to the NIH 
Guide for Care and Use of Laboratory Animals. Studies involving human subjects were 
approved by the Washington University Human Studies Committee and the Clinical 
Research Unit (CRU) Advisory Committee (an Institute of Clinical and Translational 
Sciences (ICTS) Resource Unit). Written informed consent was received from all 
participants prior to inclusion in the study. 
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RESULTS 
Development of a 13C6-leucine labeling approach and mass spectrometry-based 
method for quantifying labeled SOD1 in cell culture 
 The calculation of protein turnover by administering stable isotope labeled amino 
acids or D2O over time has been demonstrated in numerous cell culture models and in 
human CSF and plasma proteins (Bateman et al 2007, Bateman et al 2006, Bateman et 
al 2009, Castellano et al 2011, Elbert et al 2008, Mawuenyega et al 2013, Mawuenyega 
et al 2010, Ong 2012, Potter et al 2013) (Fanara et al 2012, Price et al 2012). Stable 
isotope labeled amino acids are biologically identical to their naturally-occurring 
counterparts and, unlike radiolabeled amino acids, are innocuous to both the system 
being studied and the experimental environment. SILK utilizes the administration of a 
stable isotope labeled amino acid that is incorporated during protein translation. The 
labeled and unlabeled proteins are immuno-isolated, digested into peptides, and 
analyzed using LC- tandem MS to quantify incorporation of the tracer into specific 
peptides (Figure 1A). Using 13C6-leucine labeled HEK293T cells, we identified three 
leucine-containing peptides that reliably and accurately determined incorporation of 
label (Figure 1C-E, Supplemental Figure 1). These data confirmed our ability to label, 
isolate, and measure tracer-incorporated SOD1 using LC/tandem MS. 
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Figure 1. Schematic of SOD1 isolation and MS detection method. A) Flow chart 
detailing the isolation, processing, and detection of leucine-containing SOD1 peptides. 
B) Schematic representing LC/tandem MS detection of 13C6-leucine containing peptides. 
The +6 Da shift in the leucine containing peptide KADDLGKGGNEE reflects the 
incorporation of 13C6-leucine. C-E) LC/tandem MS standard curves for the three leucine 
containing peptides used in quantifying labeled SOD1. 
	
	
95	
Development of a SILK method to measure SOD1 turnover in vivo 
Preliminary experiments revealed insufficient labeling in human CSF SOD1 
during a 9-hour intravenous infusion of 13C6-leucine (data not shown). Based on this 
observation, we concluded that CSF SOD1 t1/2 in vivo was likely on the order of days to 
weeks rather than hours. To develop the method, we labeled human SOD1 expressing 
rats by oral administration of 13C6-leucine. We used rats expressing either wild-type 
human SOD1 (WT) or mutant human SOD1 G93A protein, a well-studied mutation that 
is known to cause ALS in humans and is characterized by a predictable disease onset 
in animal models (Aoki et al 2005, Gurney et al 1994). Approximately 100-day-old 
transgenic rats overexpressing human wild-type SOD1 or G93A were orally 
administered 13C6-leucine for 7 days followed by unlabeled leucine for an additional 56 
days. Plasma, spinal cord, cortex, CSF, liver, and kidney were collected at indicated 
time points (Figure 2A) in order to model plasma free 13C6-leucine and SOD1 kinetics in 
vivo. Following detergent fractionation to immunoprecipitate soluble SOD1 from tissues, 
we used our LC/tandem MS method to detect and analyze leucine-containing SOD1 
peptides and quantify SOD1 fractional turnover rates (FTR) and t1/2 in each tissue.  
The shape of the plasma free 13C6-leucine curve followed a pseudo linear 
increase during the oral 13C6-leucine pulse and first-order kinetic decay during the chase 
with unlabeled leucine (Figure 2B). This confirmed that our oral labeling approach 
achieved sufficient 13C6-leucine incorporation into soluble SOD1 peptides with minimal 
variance between animals. The SOD1 labeling curves reflect tracer derivation from a 
direct precursor/product relationship between plasma leucine and each protein, as the 
SOD1 labeling curves intersect the plasma leucine enrichment at their peak 
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enrichments (Figure 2B). These measurements also showed that 13C6-leucine labeled 
SOD1 in the CSF could be measured, that the t1/2 of CSF SOD1 was on the order of 
days, and that the kinetics of CSF SOD1 closely paralleled the kinetics of SOD1 in the 
CNS, specifically the spinal cord. However, the changing plasma free 13C6-leucine 
enrichment over the time course presented a level of complexity in the system that 
excluded a simple calculation of SOD1 t1/2. Specifically, the linear rise and first order 
decay of the curve as well as the persistence of substantial 13C6-leucine long after the 
cessation of labeled diet reflected the slow kinetics of the oral administration method 
and the contribution of whole-body tracer recycling to long term kinetic analysis, 
respectively. As such, we recognized the need to model the system in order to account 
for the dynamics of this tracer pool and its influence on the tissue-specific SOD1 pools 
to precisely quantify in vivo SOD1 kinetics.  
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Figure 2. Kinetic data and model from SOD1 WT rats. A) Schematic of the oral 
labeling paradigm. SOD1 WT rats were fed 13C6-leucine for 7 days then chased with 
unlabeled leucine for an additional 56 days. Tissues were collected at the indicated time 
points and detergent soluble SOD1 was immunoprecipitated, digested, and analyzed by 
LC/tandem MS. B) Mole fraction labeled (MFL) plasma free 13C6-leucine and liver, 
kidney, cortex, CSF, and spinal cord SOD1 WT were plotted over time (individual 
points). Solid lines represent best-fit model curves. The shape of the plasma leucine 
curve during the 13C6-leucine labeling period reflects the pulsatile administration of the 
tracer twice daily. The slower kinetics of SOD1 WT in spinal cord, cortex, and CSF are 
reflected in the gradual rise and fall of the curves compared to the steep slopes seen in 
liver and kidney. Light red shading between 0 and 7 days represents the 13C6-leucine 
labeling period. n=3 for all time points with the exception of days 3 and 7 (n=6).  
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Kinetic modeling defined slow SOD1 kinetics 
 A compartmental model was developed to account for the shape of the plasma 
13C6-leucine time course and long-term whole-body tracer recycling (Supplemental 
Figure 2A). In this model, plasma leucine represents a central compartment where 
tracer freely exchanges with all other measured compartments and whole body protein 
or is irreversibly lost from the system. From this central compartment, forward arrows 
indicate the forward exchange of tracer into each tissue compartment. The reverse 
arrows indicate tracer return and represent the FTR, expressed as pools per day, for 
each compartment. Best-fit curves for free plasma 13C6-leucine, and spinal cord, cortex, 
CSF, liver, and kidney SOD1 are seen overlaid the raw data in Figure 2B. The shape of 
the plasma 13C6-leucine curve during labeling represents the simulated pulsatile nature 
of oral 13C6-leucine tracer administered twice a day for 7 days. The model calculated a 
t1/2 of 14.9 days for CSF SOD1, confirming that SOD1 is a relatively long-lived protein in 
this pool (Table 1). Furthermore, it showed no significant difference between SOD1 
turnover rate in the CSF and the spinal cord, suggesting that the CSF pool could serve 
as a suitable proxy for spinal cord SOD1. 
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  SOD1 WT   SOD1 G93A 
  
FTR 
(pools/d) 95% CI 
Half-life 
(d)   
FTR 
(pools/d) 95% CI 
Half-life 
(d) 
Whole body 
protein 0.063 0.057 − 0.069 11.0   0.089 0.085 − 0.093 7.8 
Liver SOD1 0.397 0.379 − 0.415 1.7   0.485 0.457 − 0.514 1.4 
Kidney SOD1 0.205 0.197 − 0.213 3.4   0.188 0.180 − 0.196 3.7 
Cortex SOD1 0.074 0.071 − 0.078 9.3   0.104 0.098 − 0.109 6.7 
CSF SOD1 0.047 0.044 − 0.050 14.9   0.074 0.070 − 0.077 9.4 
Spinal cord 
SOD1 0.044 0.041 − 0.046 15.9   0.077 0.073 − 0.081 9.0 
Liver misfolded 
SOD1             0.868 0.795 − 0.941 0.8 
Spinal cord 
misfolded SOD1             0.325 0.309 − 0.342 2.1 
Liver total 
protein 1.265 1.121 − 1.409 0.5   0.711 0.655 − 0.767 1.0 
Cortex total 
protein 0.177 0.167 − 0.186 3.9   0.127 0.120 − 0.135 5.4 
Spinal cord total 
protein 0.087 0.081 − 0.094 7.9   0.096 0.088 − 0.104 7.2 
 
 
Table 1. Model parameters for SOD1 WT and G93A turnover in ALS rats. For each 
compartment in the SOD1 kinetic model, the fractional turnover rate (FTR), 95% 
confidence interval (95% CI), and t1/2 were calculated. The data confirm the long t1/2 of 
SOD1 in CNS tissues, with SOD1 WT approximately 9-fold and 5-fold longer-lived in the 
spinal cord and cortex than in the liver, respectively. For SOD1 G93A, this relationship 
persists, with SOD1 approximately 6- and 4.5-fold longer-lived in spinal cord and cortex 
than in the liver, respectively. Between groups of animals, SOD1 G93A was generally 
shorter-lived in each tissue than SOD1 WT. 
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SOD1 WT and G93A turnover  
Although we were primarily concerned with using SILK to measure the turnover 
of SOD1 in the CSF and the CNS, our labeling method also allowed us to examine 
SOD1 turnover in several tissues within the same animal. As expected, the plasma free 
13C6-leucine served as the tracer source for all measured SOD1 pools. Interestingly, 
SOD1 turnover was significantly slower in the CNS (Figure 2B and Table 1). 
Specifically, the t1/2 of SOD1 in the spinal cord (15.9 days) and cortex (9.3 days) was 
2.8 – 9 times slower than the t1/2 from the liver (1.8 days) or kidneys (3.4 days).  
To better understand disease models, we also applied our SILK method to SOD1 
G93A rats (Supplemental Figure 2B, Figure 3A). Similar to SOD1 WT rats, the shape of 
the plasma free 13C6-leucine curve confirmed that these animals received sufficient label 
(Figure 3B). When comparing the SOD1 labeling curves, the same relative differences 
between tissues with regards to SOD1 turnover rates were evident (Table 1). When 
comparing between SOD1 WT and G93A in the same tissues, SOD1 G93A has a 1.1 – 
1.8 fold faster turnover rate with the exception of the kidneys. This accelerated turnover 
rate for SOD1 G93A agrees with previous cell culture and in vivo studies, and may 
reflect an unstable state (Borchelt et al 1994, Hoffman et al 1996, Johnston 2000, Oeda 
et al 2001, Ratovitski et al 1999).  
In addition to assaying total soluble SOD1 G93A, we were able to 
immunoprecipitate the pool of misfolded SOD1 G93A from the spinal cord in our labeled 
animals using the misfolded-specific SOD1 antibody B8H10. Best-fit curves showed that 
the misfolded G93A pool has much faster turnover rate than total soluble SOD1 G93A 
in each tissue measured (Figure 3C). Misfolded SOD1 G93A had extremely rapid 
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kinetics in the liver, faster than the total soluble SOD1 G93A pool, and much faster than 
the misfolded protein pool in the spinal cord. Interestingly, misfolded SOD1 G93A in the 
liver peaked higher than the peripheral plasma free 13C6-leucine enrichment, which 
likely reflected first-pass absorption of the orally administered tracer coupled with a fast 
turnover rate. As expected, no misfolded SOD1 could be immunoprecipitated or 
detected by LC/tandem MS in either spinal cords or livers from SOD1 WT animals (data 
not shown). These data indicate that misfolded mutant SOD1 is not unique to the spinal 
cord, that its turnover rate is accelerated relative to total soluble SOD1, and suggest 
that its low levels in the liver may be a function of its fast turnover rate. 
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Figure 3. Kinetic data and model from SOD1 G93A rats. A) Schematic of the oral 
labeling paradigm. SOD1 G93A rats were fed 13C6-leucine for 7 days then chased with 
unlabeled leucine for an additional 56 days. Tissues were collected at the indicated time 
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points and detergent soluble SOD1 was immunoprecipitated, digested, and analyzed by 
LC/tandem MS. B) Mole fraction labeled (MFL) plasma free 13C6-leucine and liver, 
kidney, cortex, CSF, and spinal cord SOD1 G93A were plotted over time (individual 
points) and modeled as previously described (solid lines). The slower kinetics of SOD1 
G93A in spinal cord, cortex, and CSF are reflected in the gradual rise and fall of the 
curves compared to the steep slopes seen in liver and kidney. C) Misfolded SOD1 
G93A was immunoprecipitated from previously labeled SOD1 G93A rat tissue with the 
α-misfolded SOD1 B8H10 antibody, digested, analyzed by LC/tandem MS, and 
modeled as previously described (solid lines). Labeled misfolded pools in both spinal 
cord and liver reveal accelerated turnover rates when compared to total soluble SOD1 
within each tissue. For both graphs, light red shading between 0 and 7 days represents 
the 13C6-leucine pulse interval. n=3 for all time points with the exception of day 14 (n=2).  
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Determination of SOD1 turnover in human CSF using SILK 
 
 Translating this SILK method to healthy, normal human research participants 
allowed us to determine CSF SOD1 turnover rates as a proxy for CNS SOD1 turnover 
rate. In these human studies, we optimized the timing of CSF and blood sampling over 
a long time period because our SOD1 WT rodent studies revealed a slow CSF SOD1 
turnover rate (approximately 15 days), and the major limitation in a human study was 
the frequency of CSF collections by lumbar puncture. Human participants consumed a 
reduced leucine-containing diet supplemented with 13C6-leucine powder for 10 days. 
Plasma and CSF were collected at indicated time points after label administration and 
processed for plasma free 13C6-leucine, total CSF protein, and labeled SOD1 (Figure 
4A). The data were then modeled as previously described where plasma free 13C6-
leucine fit to a central compartment and tracer freely exchanged with all other tissue 
compartments (Supplemental Figure 2C).  
In all subjects, plasma free 13C6-leucine enrichment achieved ~3% at the end of 
label administration. This indicated that our 10-day oral labeling strategy resulted in 
detectable and sufficient plasma 13C6-leucine enrichment for quantifying in vivo CSF 
SOD1 kinetics in the context of a controlled leucine diet. This was confirmed after 
quantifying 13C6-leucine abundance in CSF total protein (Table 2). For each subject, the 
CSF SOD1 labeling curve displayed a slow rise and fall relative to total CSF protein 
labeling, indicating a much slower CSF SOD1 turnover rate of CSF SOD1 compared to 
CSF total protein. The average CSF SOD1 and CSF total protein t1/2 was 25.0 ± 7.4 
days and 3.6 ± 1.0 days, respectively. Thus, the human CSF SOD1 turnover rate 
agreed with the slow SOD1 turnover rate observed in our rodent study. Importantly, 
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these four human studies validated our 13C6-leucine oral administration paradigm for 
quantifying long-lived protein kinetics.  
 
  
 
Figure 4. Modeling SOD1 kinetics in human CSF. A) Schematic of the oral labeling 
paradigm. Participants were placed on a prepackaged low leucine diet and administered 
13C6-leucine for 10 days, after which they resumed a normal diet. CSF and plasma were 
collected at the indicated time points and total protein or SOD1 were isolated, digested, 
and analyzed by GC-MS or LC/tandem MS, respectively. B) Data points with overlaid 
best fit model curves (solid lines) of plasma free 13C6-leucine, CSF total protein, and 
CSF SOD1 for human subject 1, C) subject 2, D) subject 3, E) and subject 4.  
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  Half-life (d) 
  Subject 1 Subject 2 Subject 3 Subject 4 Average (±SD) 
CSF total protein 2.4 4.9 3.7 3.45 3.6 ± 1.0 
CSF SOD 19.2 18.3 32.9 29.8 25.0 ± 7.4 
 
Table 2. CSF SOD1 and total protein half-life in human participants. Average half-
life was calculated for CSF total protein and CSF SOD1 from all 4 subjects. 
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DISCUSSION 
 This approach marks the first time to our knowledge that a stable isotope of an 
amino acid was administered orally for the purposes of measuring the turnover of a 
long-lived protein in human CSF and expands the repertoire of oral tracers for studying 
long-lived proteins in vivo. Similar to oral administration of heavy water, our oral 13C6-
leucine administration paradigm resulted in detectable amounts of labeled amino acid in 
the plasma and CSF, suggesting that this approach is reliable and suitable for 
quantifying protein kinetics in tissues and CSF of animals and humans. The oral SILK 
approach presents significant advantages. First, oral administration of the tracer amino 
acid is technically easier than intravenous or intraperitoneal injections in humans or 
rodents and achieves predictable labeling in plasma and tissue protein pools. Second, it 
is much safer than using radioactively labeled amino acids. Third, the time scale over 
which the labeling and tissue collection occurs facilitates the study of other long-lived 
proteins. Fourth, the LC/tandem MS is highly specific for detecting and quantifying label-
incorporated SOD1 peptides after immunoprecipitation and digestion of soluble SOD1. 
Oral administration of 13C6-leucine was well tolerated with no adverse events reported 
by the participants (data not shown), achieved detectable levels in both rodents and 
humans, and displayed predictable kinetics. Isolation and LC/tandem MS detection of 
tracer-incorporated SOD1 peptides enabled a high degree of specificity as a result of 
both antibody specificity and predicted m/z ratios. Overall, this method provides a 
specific, quantitative, and safe approach for quantifying long-lived protein turnover in 
vivo with extensive applications to many areas of biology.  
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The development of our SILK method allowed us to measure for the first time the 
rate of SOD1 turnover in the CSF of human subjects. After optimization of the method in 
humans, we found that SOD1 t1/2 in the CSF was approximately 25 ± 7 days, a number 
that reflects the long t1/2 of SOD1 WT in the CSF of transgenic rats. We also found that 
the t1/2 of CSF total protein was 3.6 ± 1.0 days. Since the CSF total protein pool is 
weighted heavily by few abundant proteins, this is not a representative sample of CNS 
protein pools. However, our rat study did show that CSF and spinal cord SOD1 turnover 
were not significantly different, suggesting that CSF SOD1 could be used as a proxy for 
the spinal cord SOD1 pool. Determination of human SOD1 turnover in the CSF has 
important implications for understanding SOD1 biology in ALS and for biomarker 
development and monitoring therapy in patients treated with SOD1 ASOs (DeVos & 
Miller 2013, Miller et al 2013, Winer et al 2013). By measuring the t1/2 of SOD1 in 
human CSF, one can predict the optimal time to measure SOD1 CSF concentrations in 
patients treated with SOD1 ASOs. The data also influence the timing and frequency of 
dosing, as well as many other pharmacodynamic aspects of ASO therapy. Indeed, one 
theoretical application of this technique involves labeling during ASO treatment to 
monitor therapeutic effects of the drug on SOD1 clearance rates.  
Although we have successfully measured SOD1 t1/2 in healthy subjects, an 
important future study will need to address mutant SOD1 t1/2 in ALS patients. Our rat 
data and previous cell culture studies confirm that mutant SOD1 t1/2 is significantly 
shorter than WT and that the degree of t1/2 reduction may be mutant dependent 
(Borchelt et al 1994, Hoffman et al 1996, Johnston 2000, Ratovitski et al 1999). The 
autosomal dominant nature of SOD1-ALS means that patients have one copy of both 
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WT and mutant SOD1. A significant advantage in our LC/tandem MS SILK approach is 
the ability to independently measure both WT and mutant SOD1 species in the same 
patient, as single amino acid changes result in detectable changes in the m/z ratios of 
predicted peptides. Future studies in these patients have the potential to determine 
SOD1 turnover as a function of age, disease status (e.g. presymptomatic versus 
symptomatic), and to what degree the SOD1 WT t1/2 is or is not influenced by the 
presence of mutant SOD1.  
In SOD1 WT and G93A rats, the tissues most affected in ALS (i.e. spinal cord 
and cortex) possessed the slowest rate of turnover. Slow turnover may explain the 
general susceptibility of the CNS in many neurodegenerative proteinopathies. Indeed, 
global proteomics approaches using stable isotopes have shown that brain proteins 
possess a slow turnover rate, even if identical proteins or protein complexes are 
compared between tissues. (Price et al 2010, Savas et al 2012). This relative difference 
between tissues agrees with our TCA-precipitated total protein data from cortex and 
liver and suggests, but does not prove, that slower protein turnover in the CNS tissue 
may result in misfolded SOD1 accumulation and pathology. Consistent with this, in 
primary culture, slow protein turnover correlates with susceptibility to toxicity (Barmada 
et al 2014, Tsvetkov et al 2013). As mutant SOD1 selectively kills motor neurons, it will 
be important to determine the relative rates of SOD1 protein turn over in specific cell 
types within the CNS.  
Our SILK labeling method could be applied to study the kinetics of a wide variety 
of long-lived proteins in both animal models and human CSF and plasma. We 
hypothesize that most intracellular proteins in the CNS have a t1/2 on the order of days 
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to weeks, making them ideal for the long-term labeling method developed here. Our 
kinetic data from TCA-precipitated total protein from spinal cord and cortex support this 
claim with a t1/2 of 7.9 and 3.9 days for SOD1 WT rats, respectively (Table 1).   
It should be noted that D2O labeling has also been successfully used for 
understanding kinetics of proteins in the CNS (Fanara et al 2012). We used oral 13C6-
leucine in this study because of the known safety of oral leucine and the high 
enrichment of the label within a single M+6 isotopomer facilitating LC/tandem MS 
analysis.  
With this study, we have demonstrated a successful SILK design that utilizes oral 
administration of a tracer amino acid for measuring long-lived proteins in rodents and 
human subjects. This technique enabled us to show that SOD1 is a long-lived protein in 
human CSF and that the t1/2 of SOD1 in the CSF correlates with that in the CNS in rats. 
The method described here has wide ranging applications that could be applied to 
measure protein turnover in a number of neurodegenerative diseases in both animals 
and human CSF (or plasma) as well as monitor the pharmacodynamics of treatments 
designed to modulate protein levels, such as ASOs, small molecules, or siRNA.  
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Sequence Precursors Product Collision Energy (V) 
GLHGFHVHE 516.754 649.32 21 
  516.754 725.336 21 
  516.754 748.388 21 
  519.764 655.34 21 
  519.764 725.336 21 
  519.764 754.409 21 
KADDLGKGGNEE 616.791 543.277 24 
  616.791 690.305 24 
  616.791 803.389 24 
  616.791 1033.443 24 
  616.791 1104.48 24 
  619.801 549.297 24 
  619.801 690.305 24 
  619.801 809.409 24 
  619.801 1039.463 24 
  619.801 1110.5 24 
SNGPVKVWGSIKGLTE 836.457 547.308 32 
  836.457 868.467 32 
  836.457 990.525 32 
  836.457 1089.593 32 
  836.457 1125.605 32 
  839.467 553.328 32 
  839.467 868.467 32 
  839.467 996.545 32 
  839.467 1095.614 32 
  839.467 1125.605 32 
 
Supplemental Table 1. Transition ions used for LC/tandem MS 
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Subject Age Gender Race 
1 66 Male Caucasian 
2 51 Male African American 
3 72 Male Caucasian 
4 74 Male African American 
 
Supplemental Table 2. Demographics of human participants labeled with 13C6-
leucine. 
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Supplemental Figure 1. Immunoprecipitation of human SOD1 transgenic rats. 
Western blot showing the successful immunoprecipitation of SOD1 from SOD1 WT and 
G93A transgenic rat spinal cord using magnetic beads covalently coupled to anti-SOD1 
antibodies. hSOD1 signifies human SOD1 and rSOD1 signifies rat SOD1. 
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Supplemental Figure 2. Kinetic models developed for this study. In each model, 
plasma leucine represents a central compartment where tracer freely exchanges with all 
other measured compartments and whole body protein or is irreversibly lost from the 
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system. From this central compartment, forward arrows indicate the forward exchange 
of tracer into each tissue compartment. The reverse arrows indicate tracer return and 
represent the FTR, expressed as pools per day, for each compartment. Dotted lines 
represent irreversible loss of tracer from the system. A) Diagram of the compartmental 
model accounting for plasma 13C6-leucine, tissue-specific soluble SOD1, and total 
protein over the full time course in SOD1 WT rats. B) Diagram of the compartmental 
model accounting for plasma 13C6-leucine, tissue specific soluble SOD1, misfolded 
SOD1, and total protein over the full time course in SOD1 G93A rats. C) Diagram of the 
compartmental model accounting for plasma free 13C6-leucine, CSF total protein, and 
CSF SOD1 over the full time course for human participants receiving a 10-day course of 
13C6-leucine followed by a normal diet. 
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Supplemental Figure 3. Correlations between the three leucine-containing SOD1 
peptides used in this study. High correlations confirm the accuracy of mass 
spectrometric quantification of tracer:tracee measurements for tissue-specific SOD1. R2 
> 0.9199 and p < 0.0001 for all groups. 
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Summary and Future Directions 
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 Research into SOD1 ALS has been ongoing for over twenty years, resulting in 
numerous hypotheses of disease mechanisms, multiple models organisms, and a 
significant number of proposed treatments. The lack of a consensus on the 
pathogenesis of ALS indicates that, even after two decades, much has yet to be 
discovered for this multifaceted disease. This dissertation presents novel findings in two 
different aspects of SOD1 mediated ALS – the initial biochemical characterization of 
cSOD1 in canine DM and insights into the tissue specificity of the disease. The 
highlights of these findings and their future directions are described below. 
 
SOD1 mutants in canine DM biochemically parallel human SOD1 and ALS 
 In Chapter 2, original work detailed the first characterization of cSOD1 mutants in 
canine DM. This was a direct extension of work done by Joan Coates’ group that first 
identified the cSOD1 E40K mutation in dogs with canine DM (Awano et al. 2009). Two 
years later, a second mutation (T18S) was discovered in Bernese Mountain dogs with 
canine DM (Wininger et al. 2011). Prior to these discoveries, only one paper had 
unsuccessfully tried to link cSOD1 to canine spinal muscular atrophy, and only in terms 
of genetic sequence (Green et al. 2002). The work described in this dissertation marks 
the first characterization of the cSOD1 protein, the findings of which strengthen the 
parallels between human ALS and canine DM.  
 Similar to hSOD1 mutants in human ALS and transgenic animals, I was able to 
show that cSOD1 mutants exist as detergent insoluble aggregates in the spinal cords of 
affected animals and that they accumulate with disease (Johnston et al. 2000, Wang et 
al. 2003). This finding suggests that mutant cSOD1 possesses a similar mechanism to 
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hSOD1 in the spinal cords of these animals, as an accumulation of SOD1 aggregates is 
a defining pathological feature of SOD1 ALS. Using a variety of in vitro assays, I also 
found that cSOD1 mutants are intrinsically less stable and prone to aggregation 
compared to the wild-type protein. This finding recapitulates the reduced stability of 
human SOD1 mutants as measured by many different biochemical assays (Münch & 
Bertolotti 2010, Ratovitski et al. 1999, Tiwari & Hayward 2003). Importantly, I was able 
to determine that both the cSOD1 E40K and T18S mutants were functional dimers with 
full enzymatic activity. This was a critical finding, as, unlike human SOD1 ALS, a 
majority of canine DM is autosomal recessive, raising the possibility of a loss of function 
mechanism for pathogenesis. My findings lend strong support for the same toxic gain-
of-function mechanism seen in human ALS.  
 
Canine DM offers an unprecedented new model to study the natural progression 
of ALS 
 With the discovery of canine DM, the ALS field gained the first ever naturally 
occurring model of disease. The fact that this disease occurs in dogs is an added 
bonus, as the medical infrastructure for canine veterinary medicine in the United States 
is well established. This facilitates the discovery of affected dogs and affords ample 
opportunity for intervention and study, including canine clinical trials. Also, as the human 
environment is frequently shared by canines, the opportunity for studying environmental 
contributions to disease in a relatively controlled or quantified setting is unique. 
Additionally, since canine DM is largely a disease of purebred dogs, the genetics of the 
disease are closely monitored and a robust market for genetic testing exists. This 
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enables a large population of dogs to be accurately diagnosed and allows for early 
detection of mutations in the offspring of carriers or affected animals.  
 A significant advantage to studying canine DM over existing transgenic animal 
models is the natural occurrence of the disease in the setting of endogenous mutant 
SOD1 levels. This closely parallels the endogenous levels of SOD1 seen in human 
ALS, offering a more physiological window into the pathogenesis of disease. Even 
though there exist transgenic animal models with levels of mutant SOD1 expression 
below endogenous mouse SOD1, such as the SOD1 G85R, L126X, L126delTT, and 
G127X mice, these animals still require multiple copies of the hSOD1 transgene for a 
disease phenotype (Bruijn et al. 1997, Jonsson et al. 2004, Wang et al. 2005, Watanabe 
et al. 2005). Canine DM allows for the study of SOD1 disease mechanisms without the 
confounds of overexpression seen in transgenic models. Another advantage with canine 
DM is the ability to further study the effects of age and environment on disease. 
Although transgenic rodent models of SOD1 ALS technically develop disease with age, 
the significantly shorter lifespan of a rodent, coupled with the dependence on SOD1 
gene copy number for a disease phenotype, creates an artificial, if not temporally 
convenient, system. Coupled with the biochemical similarities between human and 
canine SOD1 mutants described in Chapter 2, canine DM offers one of the closest 
approximations to human SOD1 ALS. 
Dog models of disease are opportune candidates for testing therapies. This is 
facilitated by the limited genetic diversity of many dog breeds, the shared environment 
with humans, willing owners, significant veterinary infrastructure, and favorable market 
forces for treatments. For example, naturally occurring canine cancers have been 
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invaluable models for testing numerous treatments in clinical trials, as many canine 
cancers share similar etiologies with human cancers (Rankin et al. 2012, Rowell et al. 
2011). Dogs also show age-related changes in cognition and even have deposition of β-
amyloid, offering opportunities for testing amyloid-lowering therapies in these animals 
(Cotman & Head 2008, Head 2013). One promising therapy that has recently completed 
a Phase I clinical trial in humans is the use of antisense oligonucleotides (ASOs) 
against SOD1 (Miller et al. 2013). These drugs have shown enormous promise in 
animal models of ALS, but the clinical trial process in humans is long and arduous. 
Using these drugs in a canine DM model can expedite the search for safer, more 
efficacious ASOs, as well as elucidating the best time to treat (e.g. early vs. late).  
 As described in Chapter 2, cSOD1 and hSOD1 share approximately 80% identity 
and a propensity to aggregate when mutated. Coupled with overlapping clinical 
presentations between human ALS and canine DM, it is reasonable to assume that 
disease mechanisms are also shared. This paves the way for future experiments testing 
current theories of human disease in the canine DM model. For example, the past few 
years have seen the advent of work describing a prion-like spreading of mutant SOD1. 
Such a mechanism had been theorized based on the geographic spread of the disease 
through the neuroaxis, affecting motors neurons closest to the site of clinical 
manifestation (Ravits & La Spada 2009). One study has shown that hSOD1 mutants, 
once misfolded, can trigger further misfolding of intact SOD1 in vitro (Chia et al. 2010). 
Cell culture systems have shown that exogenously applied aggregates of mutant 
hSOD1 could be taken up by cells via macropinocytosis, causing endogenous mutant 
SOD1 to misfold, aggregate, and self-propagate through subsequent cell divisions 
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(Münch et al. 2011). Misfolded SOD1 can also be released from dying cells as a naked 
aggregate or from live cells as exosome and spread to neighboring cells (Grad et al. 
2014). It would be interesting to determine if mutant cSOD1 aggregates possess the 
same properties of cellular uptake and SOD1 propagation. Additionally, further work by 
another lab using antibodies against misfolded-specific SOD1 epitopes demonstrated 
that co-expression of mutant hSOD1 with wild-type hSOD1 resulted in misfolding of the 
wild-type protein (Grad et al. 2011). More importantly, this group showed that the 
species-specific propagation of misfolding was dependent upon the tryptophan-32 
residue. By mutating this residue, which is unique to hSOD1 (and equine SOD1), to 
serine (as is found in most other species’ SOD1, including mouse, rat, and dog), the 
propagation of misfolding was significantly reduced. Since cSOD1 lacks a tryptophan at 
this residue, this implies that cSOD1 mutants will be unable to propagate within a cell. If 
the prion-like hypothesis of SOD1 ALS is correct, then that would signify that the 
mechanism for canine DM is dramatically different from human ALS. Therefore, further 
study into the ability of cSOD1 mutants to propagate misfolding and spread from cell-to-
cell could offer support for or detract from a prion-like mechanism for disease. 
 
SILK is a viable method for successfully measuring SOD1 protein turnover 
 Chapter 3 of this dissertation described original work developing a stable isotope 
labeling method with oral administration of 13C6-leucine in both SOD1 transgenic rat 
models and healthy human subjects. As SOD1 was hypothesized to be a long-lived 
protein in the CNS, the labeling and chase period needed to be significantly long in 
order to accurately model SOD1 turnover. This study marked the first time that stable 
	
	
130	
isotopes were used to measure SOD1 turnover in multiple tissues in an ALS animal 
model and in human CSF. The method of administering the stable isotope 13C6-leucine 
via the drinking water was validated by our ability to detect ample circulating free label 
in plasma and incorporated label in total protein and SOD1 with minimal variation. The 
pulse-chase paradigm employed for this study has significant advantages over more 
conventional methods. First, oral administration of the tracer amino acid is technically 
easier than injections in rodents and achieves predictable kinetics in plasma pools. It is 
also much safer than using traditional radioactive isotopes. Second, the time scale over 
which the labeling and tissue collection occurred (>60 days) facilitates the study of 
longer-lived proteins. Third, the LC-MS method for detecting and measuring label-
incorporated SOD1 peptides is highly specific and quantitative.  
Looking forward, this labeling method could be applied to other SOD1 mutant 
models or neurodegenerative proteins. Canine DM would be an ideal model to apply 
SILK, as this model avoids any artifacts due to transgenic overexpression that 
characterize rodent models. Administration of 13C6-leucine to dogs with canine DM 
could be easily accomplished and the fact that most of the owners elect for euthanasia 
affords an amount of control over when tissues are collected. For younger or 
presymptomatic animals, cSOD1 turnover in the CSF could be monitored as a proxy for 
the CNS. SILK would be a valuable tool for studying the turnover of other 
neurodegenerative proteins, especially those with expression in multiple tissues, such 
as TDP-43, FUS, huntingtin, androgen receptor, and others (Huang et al. 2010, Li et al. 
1993, Ruizeveld de Winter et al. 1991, Sephton et al. 2010). 
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SOD1 turnover is significantly slower in the tissues most affected in ALS 
 SILK revealed that the tissues most affected in ALS possessed the slowest rate 
of turnover. Specifically, the half-life of SOD1 WT in muscle (22.7 days), spinal cord 
(15.7 days), and cortex (9.3 days) were significantly different than in kidney (3.4 days) 
and liver (1.8 days). For SOD1 G93A, this relative difference was also seen, with SOD1 
half-life in muscle (20.5 days), spinal cord (9.0 days), and cortex (6.7 days) significantly 
different from kidney (3.7 days) and liver (1.4 days). Interestingly, these turnover rates 
correlated with the pathological progression of disease noted in many ALS animal 
models. Some of the earliest pathological changes in SOD1 animal models are seen in 
muscle tissue. For example, muscle atrophy, NMJ loss, and mitochondrial vacuolization 
and uncoupling in muscle fibers have been found to precede motor neuron loss in 
zebrafish and mouse SOD1 models (Brooks et al. 2004, Dupuis et al. 2003, Leclerc et 
al. 2001, Ramesh et al. 2010, Sakowski et al. 2012). Interestingly, selective expression 
of SOD1 in muscle was found to be sufficient to cause muscle pathology and, in one 
study, motor neuron loss in mice (Dobrowolny et al. 2008, Wong & Martin 2010). While 
research into presymptomatic muscle function and pathology in human ALS patients is 
sparse, some studies have shown mitochondrial uncoupling and reduced cellular 
respiration in patients with disease (Dupuis et al. 2003, Echaniz-Laguna et al. 2006, 
Krasnianski et al. 2005, Wiedemann et al. 1998). After mitochondrial changes in 
muscle, the next tissue affected is the CNS with the majority of pathology seen in the 
spinal cord with motor neuron loss and reactive gliosis. By correlating turnover rate with 
the temporal order of pathogenesis, these data suggest that a reduced rate of protein 
clearance may play an important role in the tissue specificity of the disease. 
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Prior to this study, only one group looked at SOD1 turnover in vivo by 
administering deuterium-labeled water to mice, chasing with normal water, and 
measuring the clearance of labeled SOD1 WT-YFP or G85R-YFP in the spinal cord 
over time (Farr et al. 2011). This group did find that the SOD1 WT half-life was relatively 
long (approximately 22 days), which agreed with our SOD1 half-life data from SOD1 WT 
rat spinal cords. They also found that the G85R mutant possessed accelerated 
turnover, but to a much larger degree than what we found for G93A. This difference in 
mutant turnover reflects the correlation between SOD1 mutant stability and half-life that 
has been repeatedly demonstrated in cell culture, with more unstable mutants having 
significantly reduced half-lives (Borchelt et al. 1994, Hoffman et al. 1996, Johnston et al. 
2000, Ratovitski et al. 1999). Indeed, future SILK experiments in SOD1 mouse models 
expressing more unstable mutants, such as G85R, G37R, and G127X, would most 
likely show rapid turnover in each tissue in comparison to SOD1 WT and G93A. As 
SOD1 ALS patients and animal models with these unstable mutations show the same 
tissue specificity of disease, this implies that the absolute rate of SOD1 mutant turnover 
is less important than the relative difference between tissues. 
 
Misfolded SOD1 turnover is accelerated relative to total soluble SOD1 
 One of the advantages in using stable isotopes to examine SOD1 turnover in 
vivo is the ability to look at multiple SOD1 pools within the same animal. When we 
looked at mutant SOD1 in the spinal cord of SOD1 G93A rats, we found a 4.2-fold 
increase in the turnover rate compared to the total soluble SOD1 G93A protein. As with 
total soluble SOD1 G93A, this reflects the increased instability of the misfolded mutant 
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protein, which is rapidly targeted for degradation. However, the magnitude of the 
increase was surprising, as the misfolded pool in the spinal cord turned over faster than 
kidney SOD1. This finding prompted us to isolate and measure labeled misfolded SOD1 
in the liver, which has been previously shown to exist at very low levels compared to the 
same pool in the spinal cord (Zetterström et al. 2007). As expected, the kinetics of this 
pool revealed a half-life of only 19.2 hours, the fastest measured in this study and 2.7 
times faster than the misfolded pool in the spinal cord. The fact that the misfolded pool 
in the spinal cord is relatively slower than the same pool in the liver, despite significantly 
faster kinetics in both pools, further supported the hypothesis that affected tissues clear 
mutant protein less effectively than non-affected tissues.  
 The significantly faster turnover of the misfolded SOD1 G93A pool explains the 
low steady state levels of this pool in the spinal cord and liver. As this is thought to be 
the pathogenic species in SOD1 ALS, these low levels must be sufficient to cause 
disease. Indeed, other more unstable SOD1 mutants, such as G85R, L126X, 
L126delTT, and G127X, cause disease in animal models at levels below those of 
endogenous mouse SOD1 (Bruijn et al. 1997, Jonsson et al. 2004, Wang et al. 2005, 
Watanabe et al. 2005). The accelerated turnover rates of the more unstable SOD1 
mutants in cell culture may reflect the relative population of these pools that is 
misfolded. For example, many of the metal-binding region mutants, such as G85R and 
H46R, exist mostly in the misfolded state as measured by proteinase K sensitivity 
assays (Hayward et al. 2002, Ratovitski et al. 1999). It would be reasonable to 
hypothesize that the relative difference between total soluble and misfolded pools with 
these mutants would be substantially less than the relative difference observed for the 
	
	
134	
G93A pools. This could be easily tested using the same misfolded-specific antibody 
immunoprecipitation utilized in our study in a 13C6-leucine mouse SOD1 G85R or 
G127X model. 
 
SOD1 is a long-lived protein in healthy human CSF 
 Chapter 3 also describes the development of a method to label healthy human 
subjects with 13C6-leucine and measure SOD1 turnover in the CSF. SOD1 is prevalent 
in the CSF at measurable and stable levels, implying that measuring its turnover could 
be used as a proxy for CNS SOD1 turnover (Jacobsson et al. 2001, Winer et al. 2013). 
Since SOD1 turnover was relatively slow in rat CSF, we reasoned that human SOD1 
would be at least as slow. Previous studies looking at β-amyloid turnover in the CSF, 
which has a half-life of a few hours, have relied on continuous or bolus intravenous 
infusions of 13C6-leucine followed by CSF sample collection every hour from a catheter 
installed in the base of the spine (Bateman et al. 2006, 2007). As our animal studies 
demonstrated the success of oral administration of 13C6-leucine and that SOD1 turnover 
in the CSF was on the order of days, we applied a modified version of our animal 
protocol to healthy human subjects. This was not without its challenges, as no study 
had previously used repeated oral doses of 13C6-leucine in humans or had measured 
remaining labeled protein so far out, where amino acid recycling would increasingly 
contribute to TTR measurements. Oral administration of 13C6-leucine in the setting of a 
controlled low leucine diet for 10 days resulted in sufficient concentration of the tracer in 
plasma, CSF proteins, and SOD1. We were able to construct a model from the data to 
incorporate the changing 13C6-leucine precursor pool over time as well as the 
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contributions from tracer recycling. This study marks the first time that a stable isotope 
was administered orally for the purposes of measuring the turnover of a long-lived 
protein in human subjects and establishes a new labeling paradigm for studying long-
lived proteins. 
 The data from labeled human subjects confirmed the long half-life of SOD1 seen 
in ALS rat CNS tissues and CSF. After optimizing our sample collection time points in 
subjects, the SOD1 half-life was approximately 25 days compared and between 2-5 
days for CSF total protein. This is comparable to the approximately 15-day half-life 
calculated for SOD1 WT in rat CSF. Additionally, our animal data indicated that CSF 
SOD1 turnover closely approximates spinal cord SOD1 turnover, meaning that the 
SOD1 turnover rate measured in human subjects could be used as a proxy for turnover 
in the CNS. This has important implications for future studies looking at CSF SOD1 as a 
biomarker in disease and in potential treatments that modulate SOD1 levels, such as 
SOD1 antisense oligonucleotides (Miller et al. 2013). 
 
SILK could be used to measure additional SOD1 pools and age-related changes 
in turnover 
 One pool that has yet to be measured in our labeled SOD1 G93A rat model is the 
SOD1 aggregates. Indeed, the accumulation of detergent-insoluble SOD1 species is a 
hallmark of disease in many animal models, including canine mutant SOD1 as 
demonstrated in Chapter 2. An interesting future experiment would involve looking at 
the turnover rates of mutant SOD1 in these aggregates in the spinal cord. Depending on 
the shape of the kinetic curve, one could learn much about the nature of these 
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aggregates. For example, if newly synthesized SOD1 was immediately incorporated into 
an aggregate, the aggregate curve should rise in line with the soluble SOD1 curve. If 
there was a delay in incorporation, then a delay in the appearance of labeled SOD1 
species in the aggregate pool would be reflected in the curve. Additionally, the turnover 
rate of SOD1 aggregates could be directly measured, addressing whether these 
aggregates are permanent structures or exist in a state of flux. Taking this idea further, 
one could measure adjustments in the turnover rate of all SOD1 species in response to 
modulation of protein clearance mechanisms.  
 As mentioned previously, age is a major risk factor for the development of ALS. 
High molecular weight species of SOD1 mutants as well as misfolded SOD1 pools 
accumulate in the spinal cord with age (Crisp et al. 2013, Johnston et al. 2000, Wang et 
al. 2002). Indeed, proteasome activity has been shown to decrease with age in normal 
mice (Keller et al. 2000). One potential use of SILK is to examine the effects of age on 
SOD1 turnover in both ALS rodent models as well as human subjects. The simplest 
comparison would be between young and old animals, or between presymptomatic and 
symptomatic. Not only could SOD1 turnover be analyzed, but global protein turnover as 
well, allowing one to distinguish between a more specific or general reduction in SOD1 
clearance with age. 
 
Using SILK to measure SOD1 turnover in individual cell populations 
 A major limitation in analyzing SOD1 turnover in whole tissues is that the 
homogenous mix of cell populations prevents looking at turnover at the level of specific 
cell types. In ALS, motors neurons are uniquely affected, yet these cells only comprise 
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4% of the volume of the spinal cord (Zetterström et al. 2011). This means that the 
turnover rate measured for spinal cord derived SOD1 most likely reflects non-motor cell 
populations. It is reasonable to assume that significant differences may exist between 
motor neurons, non-motor neurons, and glia with respect to SOD1 turnover. In fact, 
such differences have been shown with mutant huntingtin protein. Recent work using 
optical pulse-chase labeling of huntingtin protein in primary culture has shown that 
cortical neurons clear mutant huntingtin faster than striatal neurons (the cells affected in 
Huntington’s Disease) and that faster clearance correlates with longer cellular lifespan 
(Tsvetkov et al. 2013). This study provided the first indication of heterogeneity in 
neuronal populations with regard to protein clearance and then linked poor turnover of 
the ubiquitously expressed huntingtin protein to vulnerable cell populations.  
 I have already shown that the CNS, specifically the spinal cord, possesses a 
significantly slower turnover rate of both soluble and misfolded SOD1 than non-affected 
tissues. The next logical hypothesis is that different cellular populations within the spinal 
cord have significantly different SOD1 turnover rates. If SOD1 turnover plays a role in 
the cellular specificity of disease, then vulnerable motor neuron populations may have 
the slowest turnover rate of all. After all, motor neurons expressing SOD1 mutants are 
the most sensitive to proteasome inhibition and play a role in disease onset (Boillée et 
al. 2006, Puttaparthi et al. 2004). In order to address these questions with SILK, floxed 
SOD1 knock-in mice could be created and crossed to mice expressing Cre 
recombinase under cell type specific promoters. These double transgenic mice would 
then only express SOD1 in motor neurons (ChAT-Cre), all neurons (Thy1.2-Cre), 
astrocytes (GFAP-Cre), or microglia (Iba1-Cre). Following our established 13C6-leucine 
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labeling paradigm, these animals would be labeled as described in Chapter 3. The 
human SOD1 immunoprecipitated from tissue lysates would only be from the specific 
cell types expressing the protein, enabling the measurement of SOD1 turnover in 
specific cells in vivo.  
 
Using SILK to measure SOD1 turnover in patients with dominantly-inherited ALS 
 Having verified a method to measure SOD1 turnover in the CSF of healthy 
human subjects, the next step is to measure SOD1 turnover in patients with SOD1 
mutations. This will allow us to look at the role of SOD1 turnover in disease as well as 
monitor SOD1 antisense oligonucleotide therapy (Miller et al. 2013). The ease of orally 
administering 13C6-leucine to human patients over 10 days becomes a significant 
advantage to conventional intravenous methods, as mobilizing ALS patients to and from 
the hospital becomes very difficult with advancing disease. Also, our data indicate that 
we require four CSF collection time points at days 10-14, 26, 42, and 70-80, meaning 
infrequent trips to the clinic.  
 Initial studies would involve patients with the SOD1 A4V mutation, as it is the 
most prevalent in North America at 41% of SOD1 ALS (Andersen et al. 2003). This 
would enable SOD1 turnover to be measured in a homogenous patient population, as 
animal and in vitro data indicate that mutant turnover is dependent on the degree of 
protein instability. One potential problem is that SOD1 patients possess both a wild-type 
and mutant copy of SOD1. However, the A4V mutation occurs within a leucine-
containing peptide generated from endoproteinase Glu-C digestion, allowing the 
differentiation by mass spectrometry of the A4V and WT peptides and thus 
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simultaneous measurement of both wild-type and A4V mutant protein in human CSF. 
This would allow one to investigate the role of SOD1 turnover as a function of disease 
state (i.e. presymptomatic versus symptomatic), age, environment, or mutation status. 
Although one would expect to find an accelerated turnover rate for A4V relative to wild-
type protein in CSF, the more interesting questions relate to the status of the wild-type 
protein. Wild-type protein is present in SOD1 aggregates, can form heterodimers with 
certain SOD1 mutants, can be seeded to misfold in the presence of misfolded mutants, 
and exacerbates disease when co-overexpressed with mutant protein in animal models 
(Chia et al. 2010, Grad et al. 2011, Prudencio et al. 2010, Witan et al. 2008). 
Additionally, some groups have observed misfolded SOD1 WT in sporadic ALS patients 
and familial ALS due to TDP43 and FUS mutations (Bosco et al. 2010, Forsberg et al. 
2010, Pokrishevsky et al. 2012). SILK would be a powerful technique to look at the role 
of SOD1 WT protein in the setting of ALS mutations, familial ALS due to other genes, 
and sporadic disease. 
 In closing, this dissertation has described original work in two different facets of 
SOD1 ALS biology. Chapter 2 detailed the first biochemical characterization of the only 
two cSOD1 mutants found in canine DM, drawing numerous parallels with hSOD1 
mutants that further establish canine DM as an exciting new naturally occurring model 
for ALS. This model holds immense promise for understanding aspects of the disease 
that have not been forthcoming from traditional models, such as the role of age and 
environment on disease, and the data gathered in this dissertation will hopefully serve 
as a foundation for such future studies. Chapter 3 detailed the first use of SILK to 
measure SOD1 turnover in both rodent animal models and CSF from healthy human 
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subjects. In animals, the data indicate that SOD1 is a long-lived protein in the tissues 
most affected in disease, suggesting a role for protein turnover in the tissue specificity 
of ALS. In humans, applying the SILK method resulted in the first successful oral 
labeling approach to measuring a long-lived protein in the CNS and replicated the 
finding in animals that SOD1 is a long-lived protein in the CNS. Moving forward, SILK 
will be a powerful tool for looking at SOD1 turnover in additional animal models and 
human ALS patients with the goal of better understanding SOD1 biology. 
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